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CHARACTERIZATION OF POLYMORPHIC AND BLENDED DRUGS BY 
PHYSICAL-ANALYTICAL PROPERTIES 
RAJGOPAL MUNIGETI 
ABSTRACT 
The polymorphs of Tolbutamide and Nifedipine were differentiated by 
measuring their unique physical properties. Differential Scanning Calorimetry 
(DSC) and Dielectric Analysis (DEA) verified the variations in these compounds 
with different crystal structures but the same chemical constituents.  The 
crystalline-amorphous content of the polymorphs were determined based on a 
new DEA protocol. Solubility (w/w%) and spectroscopic methods clearly 
distinguished these drugs and compared favorably with the photomicrography 
of the polymorphs. Powder X-ray Diffraction (PXRD) analysis succintly showed 
differences in the various types of polymorphs. Scanning Electron Microscopy 
(SEM) supported the structural distinction and solubility. The FTIR spectra of all 
the polymorphs were reproducible and illustrated differences between 
tolbutamide and nifedipine but not within its polymorphs. 
The analytical techniques developed in this study were also used in 
analyzing blends of drugs and excipients, e.g. Aspirin and Polyethylene Glycol 
(PEG). Co-crystallization of drugs with PEG, an excepient, was measured with 
increases in the PEG heat of fusion beyond its blended concentration. The extra 
heat associated with the PEG heat of fusion is due to the crystallization of the 
 v 
amorphous drugs in the PEG matrix.  These unique co-crystallized blends will 
yield enhanced drug delivery since PEG is very water soluble.  
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OBJECTIVES 
 
 
The backbone of this thesis was to characterize drugs and excipients and 
then develop a structure vs. property relationship. The latter process guided the 
research to acquire a protocol to characterize and evaluate polymorphic drugs. 
The  structure attributes were developed by FT Infrared Spectroscopy, Powder 
X-ray Diffraction, particle size, Polarized Light Microscopy, hot stage microscopy 
and the property attributes by Differential Scanning Calorimetry, Dielectric 
Analysis, solubility forged the relationship5. The developed relationships were 
used to study drugs in a pre-formulation matrix. 
Studied and reported where the effect of PEG Molecular weight on the 
particle size and the melting temperature (Tm) and heat of fusion as well as 
solubility plus other properties. PEG is known for its water solubility and low 
toxicity. It includes applications where it is incorporated in adhesives, thickeners, 
contact lens fluids, stabilizers, friction reduction agents, plasticizers and 
solubilizing agents for drugs. The optimum PEG Molecular weight to be most 
effective as a crystalline host for drug growth was 4000 and 8000.  
Next, I characterized physical properties of PEG Blends with various 
drugs. The objective of the blend research was to evaluate low dose formulations 
with drugs and PEG 8000. Drug blends studied were Aspirin, Mefenamic acid 
and Naproxen with various ratios of PEG. A key result of this study was that the 
amorphous drug co-crystallizes with PEG to form a special drug product. Again 
 xvi 
measuring particle size, Tm, Fusion and solubility which contributed to the basis 
for the final protocol. The physical properties, structure-property relationship, 
were used to develop a characterization protocol for testing and evaluating 
other drugs by physical-analytical properties and methods.  
Property Analysis 
Thermal Analysis and solubility studies yielded many useful properties to 
evaluate PEG, drug/PEG blends and polymorphic forms of a drug from the 
sulfonylurea urea class for diabetics (tolbutamide) as well as a calcium channel 
blocker for cardiovascular disorders (nifedipine).   
Structure Analysis 
X-ray diffraction and FT Infrared spectroscopy studies yielded many 
additional structural properties to further evaluate PEG, drug/PEG blends and 
polymorphic drugs.    
Used the analytical methods to study polymorphs of nifedipine and 
tolbutamide following the scheme developed. The characterization protocol 
produced valued information on the polymorphs that will aid the pre-
formulation process 
 
 
 
 
 
 
 
 
 
 xvii 
PROTOCOL 
 
 
Drug Characterization by Physical-Analytical Techniques 
Overview 
1. Nature of the test: diverse structure property tests for evaluating drugs 
and excipients. 
2. Applicable to excipients, drugs, eutectics, polymorphs and pure drugs. 
Scope 
1. Purpose of these techniques: Quantitative and Qualitative 
2. State limitations of each method 
3. Define physical property to be determined 
 
Terminology 
1. Define all significant terms 
2. Define all abbreviations  
 
Summary of test methods 
1. Brief outline of each method 
2. Brief statement of the test method principle  
 
Significance in Use 
1. Relevance in meaning of each test method 
2. Practical uses of each test method 
3. Preformulation studies and drug design 
4. Drug manufacture conditions 
5. Stability of drugs in different forms 
6. Verification of regulatory statues 
7. Development and research of new formulations 
 
Methods 
1. DSC  
2. DEA 
3. TGA 
4. PXRD 
5. FTIR 
6. SEM 
7. Microscopic Particle size analysis 
 
Hazards 
1. warnings: Care should be taken in handling specific drugs, eg.,  
Nifedipine, should be sampled in the dark , Light sensitive. 
 
 xviii 
 
Calibration and standardization 
1. Detail instructions for calibrations: Follow instructions of instrument 
manufacture. 
2. Standardization and use of reference materials 
 
 
Procedure 
1. Sequence detailed directions: Follow instructions of instrument 
manufacture. 
2. Describe succesive steps of the procedure for each technique. 
 
Interpretation of results 
1. Directions for calculating the results 
2. List of all equations 
3. Specify significant figures 
 
Research report 
1. Detailed information required in reporting the results 
2. Significance of the multiple evaluations 
3. Determine average, standard deviation, % relative error as well as 
accuracy and repeatability 
 
References 
1. References to publications supporting or providing needed information. 
2. Keywords: identify words, terms or phrases that best represent the 
technical information reported  
 
Conclusions 
1. Summarize all data collected  
2. Compare data from different methods 
3. Site all relevant information 
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CHAPTER I 
INTRODUCTION 
 
1.1 Polyethylene Glycol Molecular Weight  
Polyethylene Glycol (PEG) is a water soluble excepient, a common 
inactive ingredient in solid dose tablets. PEG in general is a series of 
condensation polymers of ethylene oxide and water with the general formula 
H(OCH2CH2)nOH, where n is the average number of repeating oxyethylene 
groups typically from 4 to about 180. The low molecular weight (MW) numbers 
from n=2 to n=4 are diethylene glycol, triethylene glycol and tetraethylene glycol 
respectively, which are produced as pure compounds. The low molecular 
compounds up to 700 are colorless, odorless, viscous liquids with a freezing 
point from -10ºC (diethylene glycol), while polymerized compounds with higher 
MW than 1,000 are wax-like solids with melting points up to 67ºC for n=180. The 
abbreviation PEG is titled with a numeric value that indicates the average MW. 
One common feature of PEG appears to be its water-soluble property. The wide 
range of chain lengths provides identical physical and chemical properties for  
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use as an excepient. Typically PEG 8000 is currently used in fabricating 
compressed tablets.  
PEG is known for its water solubility and low toxicity. It includes 
applications where it is incorporated in adhesives, thickeners, contact lens fluids, 
stabilizers, friction reduction agents, plasticizers and solubilizing agents for 
drugs1. PEG is an interesting model system to assist in interpreting thermal 
analytical techniques with its wide available molecular weight which represents 
a diversity of structures that result in varying thermal properties. This DSC tool 
can characterize solids or gels in the pharmaceutical field. Phase diagrams of 
systems including PEG with various MWs and sodium tetraphenylborate 
yielded various eutectic relations2.  
Super cooling suppression of microencapsulated n-tetradecane was 
successfully characterized using DSC. Super cooling of the system can be 
effectively implemented when the blend contains 2-4 % tetradecanol. The heat of 
fusion of n-tetradecane decreases with increase in nucleating agent. Alvarado, 
Marsh, Sohn, Vilceus, Hock, Phetteplace, and Newell found in their analysis the 
percent relative error fluctuated between ±2% which lead to their confidence that 
the DSC technique used in this research provided reliable, accurate and 
consistent data3.  
PEG is known to improve the degree of dissolution and/or time of certain 
active chemicals in the gastric media. Knowledge of the phase diagram and effect 
of MW are fundamental for PEG. The solidification process of PEG 4000 was 
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determined and the average parameter was 1.43. Temperature-cooling and rate-
transformation diagrams were constructed for a wide range of conditions. These 
researchers found a better understanding of the kinetics of crystallization4. Jiang 
prepared two novel low molecular weight PEGs for the solution synthesis of 
oligosaccharides5.  
High MW PEG has a potential to function as a surrogate mucin within the 
intestinal tract of the test host. It apparently inhibits key interactive events6. 
Physical chemical properties of a binary system glibenclamide and PEG 4000 
were studied by Barsch and Griesser7. The glibenclamide, mainly amorphous 
after melting and solidifying was prepared by a 10 % solution with PEG and 
resulted in enhanced solubility compared to physical mixtures. The solubility 
and dissolution rate of the drug increases clearly with decreasing drug/polymer 
ratio.  
Our study was advanced to extend the current knowledge of PEG 
properties by determining their DSC values for a wide variety of PEGs with 
varying molecular weights. The MW studied range from 194 to 23,000. The ten 
different MWs were examined in a DSC controlled Heat-Cool-Heat-Cool-Heat 
(HCHCH) cycle. This allowed us to determine the repeatability of the observed 
melting temperature (Tm), melting peak temperature (Tmp), heat of fusion (∆Hf), 
crystallization temperature (Tc), crystallization peak temperature (Tcp) and the 
heat of crystallization (∆Hc). We further determined the degree of super cooling 
by subtraction i.e., ΔT = Tmp – Tcp which appears to increase with molecular 
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weight. The MSDS8 of PEG (CAS No. 25322-68-3) indicates an increase in melt 
temperature with MW for 400 – 6000. We have extended the range and curve 
fitting the MW vs. Tmp, found a polynomial curve fit with an R2 of 0.97 compared 
to our curve fit of the literature9 values with a R2 of 0.99. 
 
1.2 Polyethylene Glycol on the Crystallinity of Drugs 
Electrical Conductivity Analysis (ECA) by Dielectric Analysis (DEA) 
differentiates drug melting, solid-solid transition and amorphous/crystalline 
content well below the melt temperature for a number of drugs. A set of USP 
melting standard drugs were evaluated by DSC/DEA to study the structure-
property relationship. The repeatable amorphous content is determined below 
the Tm by comparing the change in conductivity for: the crystalline drug at the 
solid-liquid transition, melting of a semi-crystalline drug and the amorphous 
drug with no definitive conductivity change but a conductivity of ≈106 to 107 
pS/cm in the liquid temperature range. Overlaying multiple thermal analysis 
techniques allows for establishment of a wide variety of physical properties. DSC 
and DEA in combination revealed unique drug properties. DEA-ECA data for 
each drug/blend studied occurred 8-25ºC below the DSC Tmp. The 2nd DEA heat 
after cooling of all the crystalline drugs studied had a significant and greater 
repeatable conductivity than the 1st DEA heat. The 2nd and 3rd DEA tests on the 
same sample represented the loss of crystallinity and increase in amorphous 
properties. The latter observation was validated by photomicrography11. 
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Riga, Golinar and Alexander determined the melting characteristics of 
United States Pharmacopeias (USP) set of standard drugs12. DSC melting profile 
of Vanillin with a melting of 82-84ºC and a ΔHf 144 J/gm was used as a standard 
in our studies12. 
Chakravarty, Alexander, Riga and Chatterjee prepared solid dispersions 
of tolbutamide with a hydrophilic carrier, PEG 8000. Their studies revealed the 
amorphous nature of the drug within the PEG matrix at greater than 40% PEG. 
They conclude that the formulation of 80% PEG - 20% tolbutamide dispersion is 
a suitable concentration for increasing the dissolution of a poorly water soluble 
drug 13. 
Pielichowsky and Flejtuch studied blending of PEG and selected 
fattyacids by DSC. They reported blending with PEG originally a helical 
structure becomes a planar zigzag structure and miscibility strongly influenced 
by the stereochemical order of poly(methyl methacrylate) (PMMA) 14. Atactic 
and syndiotactic PMMA were found to be incorporated into the amorphous 
phase between the crystalline PEG lamellae. Blends with isotactic PMMA had a 
structure consisting of alternated crystalline and amorphous lamellae of PEG 
with the PMMA segregated in interfibrillar regions15-16. 
Omar, Let, Seng and Rashid discovered that blends of hydrogenated Palm 
oil and Palm oil crystallized with time. These blends post hardened upon 
storage, but with no transformation of the polymorphs present. Post hardening is 
interpreted as crystal networking after crystallization. The trapped oil in between 
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crystals just after crystallization can crystallize upon storage which causes the 
whole system to become harder or brittle17. 
In developing a new Active Pharmacy Ingredient (API), particle design 
can be complex through the crystallization process. The properties, such as 
crystal size, habit and degree of agglomeration influence the crystallization 
process and are important for the formulation of the API. To develop a solid API 
that meets the need of the formulation and can be crystallized reproducibly, one 
must better understand the possibilities of the crystallization process. 
Beckmann18 further demonstrated that varying the crystallization process in a 
standard stirred tank reactor with slight modifications showed a wide variation 
of crystal habits: small platelets, rhombs, agglomerates, twinned and large 
crystals. A great deal can be learned about the melting and crystallization 
process by sampling a batch and imaging the crystals. 
A great deal can be learned about chemical blends by evaluating results of 
polymer blends. Sheth etal.19 prepared and characterized biodegradable polymer 
blends of poly(lactic acid) (PLA) and PEG. PLA and PEG were melt-blended and 
extruded into films at various ratios. DSC and Dynamic mechanical analysis 
(DMA) of these blends were miscible to partially miscible depending on the 
ratio. At greater than 50% PEG the blend morphology was controlled by the 
increase in crystallinity of PEG. The latter resulted in an increase in modulus and 
corresponding decrease and elongation at break. The thermal analysis tests 
concluded that PLA and PEG form miscible blends in compositions less than 
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50/50. Both components in the blends were able to crystallize and the presence 
of PEG was found to enhance the crystallization of PLA.  
Thermal Analysis had been used in the pharmaceutical industry for an 
extended period of time20-24. Giron et al. instituted diverse applications in using 
thermal analysis in the pharmaceutical industry. Giron, Goldbronn and Riechon 
investigated thermal analysis methods for pharmacopeia materials. Roy et al. 
characterized physical mixtures and directly compressed tablets of sulfamerazine 
polymorphs. Roy‟s study implied in-vitro release characteristics.   
The objective of this research is to evaluate low dose formulations with 
drugs and a known water soluble excepient, for example PEG 8000. Drug blends 
were studied of Aspirin, Mefenamic acid and Naproxen with various ratios of 
PEG. A key result is that the amorphous drug co-crystallizes with PEG to form a 
unique special drug product. 
1.3 Polymorphs 
The existence of pharmaceutical substances as polymorphs, pseudo-
polymorph or solvates is of immense interest in research and drug development. 
They cause important variations in the preparation of many pharmaceutical 
dosage forms. Physicochemical properties of polymorphs effect melting, 
electrical conductivity, crystal shape, color, dissolution rate, stability, solubility 
and solid state reactions. Polymorphism is defined as the ability of the same drug 
or substance to exist as two or more crystalline phases that have different 
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arrangements of the molecules in the crystal lattice. This study reports on the 
polymorphic forms of Nifedipine and Tolbutamide 
The optimum polymorph for the development is thermodynamically 
stable under ambient conditions. This option is chosen to avoid the risk of solid 
state conversion, i.e., avoiding a metasatble form. However, metastable forms 
can yield to enhanced solubility. Therefore this study includes the 
characterization of various polymorphs by their solubility characteristics and 
thermal properties. Carlton reviewed a variety of experimental methods that 
were used to study polymorph stability25. His and the current research will 
conclude with a protocol including Carlton‟s work and further developed by this 
study. These protocols are based on the premise that at least two methods with 
different physical principles are needed to verify results. Heats of transition and 
fusion accompanying phase changes are key to Carlton‟s comparison of the 
methods used for determining polymorph stability25. 
Park, Evans and Myerson determined the solubility of polymorphs using 
DSC. They examined both stable and metastable polymorphs of glycine, 
carbamazepine and mefenamic acid.  They were identified to be enantiotropic 
with measured transition temperatures. They used heat flow derivative curves, 
where the saturation point and therefore the solubility at known percentages are 
given by the peak of a heat flow curve. They observed accurate results when 
comparing conventional solubility techniques and this DSC method26.  
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Pudipeddi and Serajuddin raised the important question: “How big is the 
impact of polymorphism on solubility?” They conclude that it is not possible to 
draw any conclusion regarding the impact of solubility and bioavailability of 
polymorphs. This impact depends on additional factors for example, solubility 
difference, dose, and formulation factors27. 
Chan, Fleming, Kazarian, Vassou etal.28 studied the Raman and Fourier 
Transform Infrared (FTIR) spectroscopy of nifedipine under controlled relative 
humidity conditions. They observed that amorphous nifedipine was less stable at 
high humidity and converted into the thermodynamically more stable crystalline 
forms. The inter molecular hydrogen bonding interactions were detected in α 
and β (Form A and B in this study) crystalline forms, where the β and 
amorphous polymorph convert to α Form with time or humidity. The dissolution 
properties and drug bioavailability of a poorly water soluble drug is significantly 
related to its molecular state29.  Relative humidity has a pronounced effect on the 
stability on the drug forms30. These authors desired to understand the effect of 
the various environmental properties for example, relative humidity, on 
pharmaceutical preformulations. They believed this knowledge would assist new 
formula/manufacturing process for more effective and consistent drugs28. They 
observed that nifedipine exists in 3 different polymorphic forms and one 
transient polymorph by spectroscopy. 
Nikolic etal.31 reported the FTIR, near IR and proton NMR of cyclic ethers 
a O-electron donors to the N-methylpropionamide (NMP). The structure of the 
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amide interaction with Tetrahydropyran (THP), a cyclic ether, is similar to the 
interaction of 1,4-Dioxane, another cyclic ether, with nifedipine. Complexes of N-
H---O hydrogen bonding are similarly observed in our FTIR study. 
Ciara, Robbertse etal.32 studied the x-ray structure of the solvated 
nifedipine polymorph with 1,4-dioxane. They noted that the solvent molecules 
are located in isolated cavities in the crystal, yielding a very stable solvate. 
Desolvation of this polymorph disrupted the crystal structure at 150-153oC i.e., 
50oC above the boiling point of 1,4-dioxane. After desolvation, a monoclinic 
polymorph with a melting point of 174oC (identified in this study as Form B) was 
observed. The dioxane solvate is more soluble than Form B. They also detected 
that the solubility of the nifedipine amorphous form was more soluble than the 
pure form. Grinding slightly increased the crystallinity of the amorphous form 
due to partial transformation to a crystalline polymorph. The pulverized 
amorphous polymorph was more soluble than unpulverized.  
Miyazaki etal.33 examined the relative contributions of molecular mobility 
and thermodynamic factor, the relationship between glass transition (Tg) 
temperature and crystallization rate for amorphous nifedipine. They discovered 
that factors other than the molecular mobility affect the crystallization rate of 
amorphous nifedipine. 
The tolbutamide polymorphs Form I and Form III are differentiated by 
PXRD, FTIR and Hot Stage Microscopy (Burger34; Simmons35 and Leary36). Rowe 
and Anderson report that the polymorphs of tolbutamide have varying solubility 
  11 
values37. Prismatic plate-like Form I crystals convert to needle-shaped Form III 
crystals at ambient temperatures. The transition temperature viewed by Hot 
Stage Microscopy was between 25 and 95oC. The crystalline modification was 
observed at room temperature in 11 solvents e.g. ethanol, chloroform, 
acetonitrile, isopropyl alcohol, dioxane and octanol. More effective solvents 
promoted faster conversions with the rate of polymorph change varying with 
solubility. Octanol promoted a slow change from one form to another. The 
solubility in octanol for Form III at 30oC is lower than Form I, i.e, 19 mg/mL for 
Form III and 24 mg/mL for Form I. FTIR confirmed the microscopic evaluation. 
The driving force for conversion is based on a small free energy difference of 
Form I and III and low solubilities at or near room temperature. Form I appears 
to be metastable and eventually changes to Form III. Conversion can be 
accelerated by strong agitation and catalytic factors.  
Chakravarty, Alexander, Riga and Chatterjee38 prepared two polymorphic 
forms of tolbutamide. DSC, PXRD optical microscopy and solubility studies 
concluded that Form A is the same as Form I35 and Form O is similar to Form III. 
Plate like crystals for Form A (Form I) and clusters of small needle shaped crytals 
(Form O) were observed by optical microscopy. They showed clearly that Form 
A is a strong contender for pre-formulaiton studies.  
Sonoda etal.39 point out that it is very important in pharmaceutical studies 
to produce, discover and isolate polymorphs of an API and to control or identify 
polymorphic transitions. They reported that a cyclic oligosaccharide derivative 
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was used to detect intermediate metastable polymorphs during primary stages of 
crystallization. This study indicates that cyclodextrin complexes can be used to 
stabilize and isolate metastable forms that occur at an early stage of tolbutamide 
crystallization. The techniques can be a valuable means for the characterization 
of new polymorphs.  
Kawashima etal.40 prepared tolbutamide aerosil blends with Forms III and 
IV. Form II blends were obtained when porous silica was used in the 
formulation. The solubility of tolbutamide was increased when blended with 
hydrophilic silica when compared with the original Form I or Form II. The 
average particle size of the resulting dispersions was measured (4.3±0.2 μm) and 
a factor in the enhanced dissolution of the solid dispersions.  
Variations were observed in the dissolution of tolbutamide by a 
traditional Chinese Medicine, Sho-saiko-to were studied41. In the presence and 
absence of Sho-saiko-to the solubility was evaluated. The API was determined by 
a HPLC assay. The results indicate that the preparations studied had an 
inhibitory effect of the dissolution of tolbutamide.  
Kimura, Hirayama and Uekama42 characterized tolbutamide polymorphs, 
Forms II and IV and their polymorphic transitions. The apparent dissolution rate 
and the solubility of Form IV were identical to that of Form II, since Form IV 
converts to Form II during the solution process. Form II and IV had higher 
dissolution rates and solubility than that of Form I and II. These dissolution 
characteristics of the various polymorphs of tolbutamide were also observed in 
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the oral absorption behavior in dogs. Bioavailability decreased in the order Form 
IV ≈ Form II > Form III > Form I. This procedure in evaluating tolbutamide 
polymorphs is helpful in identifying solid tolbutamide. This scheme gives the 
basis for design of solid polymorphic formulations.  
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CHAPTER II 
 
INSTRUMENTION AND METHODS 
 
 
 
Methods that have been used to characterize Pharmaceutical products 
include dissolution testing, thermoanalytical methods (differential thermal 
analysis and hot stage microscopy), calorimetric analysis of the solution or 
melting enthalpy for calculation of entropy change, X-ray diffraction, 
spectroscopic methods (IR spectroscopy), and microscopic methods (polarization 
microscopy and scanning electron microscopy).  X-ray diffraction, optical 
microscopy will be discussed in subsequent chapters.  These methods are used to 
characterize the polymorphs and to differentiate between various polymorphs of 
the drug, also in blends where the drug is only partly molecularly dispersed and 
physical mixtures of drug and carrier.  Since blends are so complex, it is difficult 
to differentiate between molecularly dispersed and non-molecularly dispersed 
systems, and analytical methods may give disparate results.   
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2.1   Differential Scanning Calorimetry 
Thermal analytical techniques have become an integral part of the 
development of modern medicine because their response to thermal stresses is 
such an important aspect of the formulation of stable compounds.  DSC is a 
widely used thermal analytical method because it provides comprehensive 
information about the physical and energetic properties of a compound.  One can 
easily obtain accurate results, and with the development of modulated 
temperature programs, micro-scale test configurations, robotic systems, and 
combined DSC-spectroscopic instrumentation, it is likely to remain at the 
forefront of pharmaceutical thermal analysis. 
Instrumentation 
DSC provides quantitative information about endothermic, exothermic 
and heat capacity changes as a function of time (such as melting, purity and glass 
transition temperature).  The system consists of a two-pan configuration, sample 
and reference, and they are maintained at the same temperature and the heat 
flow required to keep the temperatures equal is measured.  Hence, DSC plots are 
obtained as the differential heating rate (in units of watts/second, 
calories/second, or Joules/second) versus temperature.  The area under the peak 
is directly proportional to the heat absorbed or evolved by the thermal event, and 
integration of the peak areas provides the heat of reaction (Joules/gram). 
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Sample Preparation 
Careful preparation of the sample and appropriate selection of 
experimental conditions (heating rate, sample size) controls the success of the 
DSC experiments.  DSC sample pans are small, metal pans that optimize thermal 
conductivity.  The pans are supplied by the manufacturer of the DSC and are 
made of aluminum alloy, platinum, stainless steel, or silver such that minimal 
reactions occur with the sample.  The pans may be open, covered, sealed, or  the 
lid can contain a pin-hole, and are used with a reference pan of the same 
configuration, filled with an inert material, such as alumina or air.  The masses of 
both the sample and reference pans should be matched to obtain accurate 
quantitative results.  Sealed pans are used to prevent heat-induced liberations of 
the sample or one of its reaction products.  Pin-holes are used for moderate 
sample containment, exposure to the reactive gas, and to avoid bursting at 
extreme temperatures.   
Pharmaceutical sample sizes are generally between 3-5 mg, and 
reasonable results can be obtained with less than 1 mg.  The small samples are 
preferred because they normally experience fewer thermal gradients and save on 
material requirements.  Powdered samples should be slightly pressed onto the 
bottom of the pan to ensure good thermal contact, especially for low density 
materials.  Particle size and shape parameters can affect the packing of the 
material, and grinding the powdered sample may be necessary to achieve 
reproducible results.  Samples should also be weighed at the start and end of 
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each analysis if quantitative estimates of heat capacity and enthalpy of fusion 
(energetic parameters) are of interest.   
Experimental Parameters 
Important experimental parameters that need to be properly determined 
include the start and end temperature of any heating and cooling stage, 
isothermal holds, the scan rate, calibration parameters, and purge gas type and 
flow rate.  It is recommended to set the start temperature sufficiently below and 
the final temperature above the temperature of interest to achieve temperature 
control and a steady baseline before any recorded transition.  Heating rates can 
range from 1°C min-1 to 100°C min-1 with accurate results as well as isothermal 
conditions.   
Calibration 
Proper calibration of the instrument is imperative to obtain reliable 
results.  Calibration should be done as close to the transition temperature of 
interest as possible with use of standards such as indium, tin, bismuth or lead.  
Also, calibration is required at each scan rate used and in both heating and 
cooling cycles to obtain the most accurate results.  Accurate results can be 
acquired by using high purity calibration standards and clean DSC sensors. Well 
defined standards and calibration procedures are especially important when 
comparing results from different instruments or at different times.  Standard 
procedures can be obtained from the American Society of Testing of Materials 
(ASTM). 
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Single Component Characterization 
Single components can exhibit thermal behaviors such as melting, 
crystallization, boiling, sublimation, dehydration, desolvation, solid-solid-
transitions, glass transitions, and polymorphic transitions and are plotted as the 
differential rate of heating versus temperature.  The transitions may be 
exothermic or endothermic and are seen in Table I.  A DSC scan of an amorphous 
sucrose sample undergoing glass transition (Tg), exothermic recrystallization (Tc) 
and enthalpy (ΔHc), endothermic melting (Tm) and enthalpy (ΔHf), and onset of 
degradation is seen in Figure 1.  It is important in DSC analysis to define the 
transitions by the onset (To), extrapolated onset (Te), and peak temperature (Tm), 
as seen in Figure 2.   
 
Table I   Enthalpic transitions observed by DSC or DTA 
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Figure 1   Differential scanning calorimetry of sucrose 
 
Figure 2   Differential scanning calorimetry showing onset temperature of 
melting, extrapolated onset melting temperature, enthalpy of fusion, and peak 
melting temperature 
 
Melting Points 
The melting transition occurs from the ordered solid state to the 
disordered liquid or molten state.  DSC can provide accurate, unambiguous 
melting temperatures which is an endothermic process in which the sample takes 
in a net quantity of heat (molar heat of fusion).  A pure crystalline compound is 
expected to give a sharp melting peak, although impurities or crystal defects lead 
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to broadening and shifting to lower temperatures.  The shape, peak height, and 
width of the melting endotherm are each determined in part by the purity.   
The onset melting temperature occurs where the transition begins to 
deviate from the baseline, as seen in Figure 2.  The extrapolated onset melting 
temperature is the temperature at the intersection of the extrapolated baseline 
prior to the transition with the extrapolated leading edge of the transition.  The 
enthalpy of fusion (ΔHf) or area of the endothermic transition is affected by the 
selection of the baseline.  Generally, the baseline of the melting endotherm is 
obtained by connecting the point at which the curve leaves from the baseline to 
where it rejoins the baseline.   
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2.2   Dielectric Analysis 
Dielectric analysis is a technique used to determine the molecular motions 
and structural relaxations present in materials possessing permanent dipole 
moments. It measures the electrical response of a material with respect to time, 
temperature and frequency. Capacitance and conductance are measured to 
obtain the dielectric constant, or permittivity (ε') which is proportional to the 
capacitance, and the dielectric loss (ε'') which is proportional to the conductance. 
Unlike DSC, DEA can be used to identify the secondary relaxations present in 
drugs, surfactants and polymers as long as the secondary group has a net dipole 
moment. The DEA can accommodate testing of various forms of samples, i.e. 
gels, liquids, solids, powder, and thin films.  
Dielectric analysis measures two fundamental electrical characteristics of a 
material capacitance and conductance-as functions of time, sampling frequency 
and temperature. The capacitive nature of a material is its ability to store 
electrical charge, and the conductive nature is its ability to transfer electric 
charge. These electrical properties are related to molecular activity, allowing for 
probing the chemistry, rheology and molecular mobility of drugs or polymers. 
For example, the material to be analyzed is placed between two electrodes while 
an alternating (sinusoidal) electrical field is applied. This produces polarization 
within the sample, causing oscillation at the same frequency as the field but with 
a phase angle shift δ. The measured current is separated into capacitance and 
conductive components. Capacitance (induced dipoles and alignment of dipoles) 
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can be determined by measurements of permittivity ε‟, and conductance (dipole 
loss factor and ionic conductance) is proportional to loss factor ε‟‟. The complex 
dielectric constant ε* consists of both the “real” (permittivity) and the 
“imaginary” (loss factor) parts: 
'''*  i  or   ε*  = 22 )''()'(    
 
With the loss tangent tanδ being the ratio of ε‟‟ and ε‟. Both loss factor and 
permittivity are frequency and temperature dependent. The dependence of ε‟ 
and ε‟‟ on sampling frequency results from the fact that a finite amount of time is 
required to align the dipole with changing electrical field. When dipoles are 
excited by moderate frequencies, they have enough time to become oriented, and 
their permittivity ε‟ is high while ε‟‟ is low. But when the frequency becomes so 
high that the dipoles can no longer follow the field, the dielectric constant falls 
precipitously and the material shows dispersion. This phenomenon is also 
followed by a sharp increase in dipole loss, resulting in a peak in ε‟‟. 
Chemicals and polymers with high permanent dipole moments (such as 
liquid crystals) show dispersion at significantly higher frequencies and have 
larger permittivity values than polymer molecules with weak or induced dipole 
moments. Increase in temperature of the media usually increases values of 
critical frequencies at which dispersion occurs. 
Plot of ε‟‟ vs. ε‟ (known as Cole-Cole plot) is a semicircular arc with its 
highest point corresponding to a critical frequency where dispersion occurs. The 
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dielectric behavior of complex chemicals or polymers quite often can be 
characterized by a distribution of relaxation times rather than by a single 
relaxation time, leading to departure from a perfect semicircular arc, or 
appearance of more than one arc if relaxation times of polymer components are 
very different. At very low frequencies, the Cole-Cole plot exhibits a straight line. 
This is due to conduction and interfacial (Maxwell-Wagner) polarization resulted 
from accumulation of charges at electrode interfaces. The higher the conductance 
of the conducting material, the higher is the frequency at which interfacial 
polarization occurs. 
Impedance/dielectric thermal analysis, while providing a wealth of 
information about chemical-electrode interactions, electrode kinetics, and 
solution composition, is an instrumentally complicated technique requiring 
sophisticated instrumentation and component operators. Cyclic voltammetry 
and dielectric spectroscopy have simpler instrumentation. Both methods provide 
information on the basis of relatively straightforward analysis of charge-transfer 
(cyclic voltammetry) kinetics by detection of various peaks or bulk properties of 
drugs or polymers by sampling permittivity or loss factor at selected frequencies. 
Parameters measured in DEA: 
- Single Surface Gold Ceramic Sensor: IDT (interdigitated transducer) 
- Permittivity [e‟] = dipole content 
- Loss factor [e”] =energy align dipoles & move ions 
- Frequency (f) = A.C. frequency in Hz 
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- Conductivity = [e” * f * constant] PS/cm 
- Complex Permittivity = [e‟2 +e”2]1/2 
- Debye Plot: Tan Delta [e”/e‟] vs log f 
 
                                          Figure 3: Dielectric Analyzer 2970 
 
2.3 Spectroscopic techniques 
2.3.1 Ultraviolet-Visible Spectroscopy  
An UV/Vis spectrum is essentially a graph of light absorbance vs. 
wavelength in a range of ultraviolet or visible regions. Such a spectrum can often 
be produced directly by a more sophisticated spectrophotometer, or the data can 
be collected one wavelength at a time by simpler instruments. Wavelength is 
often represented by the symbol λ. Similarly for a given substance, a standard 
graph of the extinction coefficient (ε) vs. wavelength (λ) may be made or used if 
one is already available. Such a standard graph would be effectively 
“concentration-corrected” and thus independent of concentration. For the given 
substance, the wavelength at which a maximum absorption in the spectrum 
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occurs is called λmax. The Woodward-Fieser rules are a set of empirical 
observations which can be used to predict λmax, the wavelength of the most 
intense UV/Vis absorption, for conjugated organic compounds such as dienes 
and ketones. This spectrum can be used qualitatively to identify components in a 
sample as each component has their own unique absorbance spectrum. 
 
2.3.2   Fourier Transform InfraRed Spectroscopy 
Sampling: 
There are no good solvents which are transparent in the full length of an 
interested region. Therefore it is very difficult and also time consuming step in 
analysis by FTIR. There are different sampling techniques for different type of 
samples such as gases, solutions, liquids and solids.  
For solids, spectra are obtained on dispersions of the solid in a liquid or 
solid matrix. In these techniques the samples are ground till its particle size is 
less than the wavelength of the radiation in order to avoid the effects of scattered 
radiation.  
Mulls: 
Infrared spectra of solids that are not soluble in an infrared-transparent 
solvent or are not conveniently pelleted in KBr are often obtained by dispersing 
the analyte in a material oil or fluorinated hydrocarbon mull. Mulls are formed 
by grinding 2 to 5 mg of the finely powdered sample (particle size < 2 µm) in the 
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presence of one or two drops of a heavy hydrocarbon oil (eg., Nujol). If 
hydrocarbon bands are likely to interfere, Fluorolube, a halogenated polymer, 
can be used instead. In either case, the resulting mull is then examinated as a film 
between flat salt plates. 
 
 
2.4   Solubility 
Solubility is a physical property referring to the ability for a given 
substance, the solute, to dissolve in a solvent. It is measured in terms of the 
maximum amount of solute dissolved in a solvent at equilibrium. The resulting 
solution is called a saturated solution. Certain substances are soluble in all 
proportions with a given solvent at a given temperature, eg, ethanol in water. 
This property is known as miscibility. 
Under various conditions, the equilibrium solubility can be exceeded to 
give a so-called supersaturated solution, which is metastable. The solvent is often 
a liquid, which can be a pure substance or a mixture. The species that dissolves, 
the solute, can be a gas, another liquid, or a solid. Solubilities range widely, from 
infinitely soluble such as ethanol in water, to poorly soluble, such as silver 
chloride in water. The term insoluble is often applied to poorly soluble 
compounds, though strictly speaking there are very few cases where there is 
absolutely no material dissolved. 
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The solubility of a solid in a relevant solvent medium is a crucial 
characteristic. Solubility is defined as the concentration of the dissolved solid (the 
solute) in the solvent medium, which becomes the saturated solution and which 
is in equilibrium with the solid at a defined temperature and pressure. The 
solubility depends on the physical form of the solid, the nature and composition 
of the solvent medium, the temperature and pressure. The most common solvent 
media are liquids or liquid mixtures which give rise to solid solutions of the 
solute. Less common solvent media are solid phases, which act as the “host” for 
the solute species that are present as “guest” molecules to form a solid solution 
of the solute. Solubilities may be expressed in any appropriate units of 
concentration, such as the quantity of solute dissolved (weight or number of 
moles) divided by the quantity either of solvent (weight, volume, or any number 
of moles) or of the solution (weight, volume, or any number of moles).  
For a given solid material, a progressive reduction of particle size 
corresponds to an increase in the surface/volume ratio and the escaping 
tendency of the molecules until the nature of the surface dominates the 
properties of the material. Solubility of a solid at a given temperature increases 
exponentially with decreasing radius of the particle. The smaller the radius of the 
particle, the higher the chemical potential (partial molar free energy) of the 
molecules in the particle will be, and hence the greater the solubility. The small 
but definite increase of solubility with decreasing particle size for microscopic 
solid particles accounts for the increase in the average particle size when crystals 
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of various sizes are allowed to age in contact with a saturated solution (the 
mother liquor). This phenomenon, known as Ostwald ripening, occurs because a 
smaller particle, having a higher solubility, will dissolve in the unsaturated 
solution that is saturated with respect to larger particle of lower solubility. 
Conversely, a larger particle having a lower solubility will grow in the 
supersaturated solution that is actually saturated with respect to smaller particle 
of higher solubility. Larger particles will therefore grow at the expense of smaller 
particles, and the concentration of the “saturated” solution will decrease 
asymptotically. This phenomenon occurs as a precipitate is allowed to age in 
contact with its mother liquor. Other factors being equal, this process takes place 
more rapidly at a higher temperature according to the theory of reaction rates.  
Factors affecting solubility: 
Solubility is defined for specific phases. For example, the solubility of 
aragonite and calcite in water are expected to be different, even though both are 
the same chemical substance (calcium carbonate). 
The solubility of one substance dissolving in another is determined by the 
balance of intermolecular forces between the solvent and solute and the entropy 
change that accompanies the solvation. Factors such as temperature and pressure 
will alter this balance, thus changing the solubility. 
Solubility may also strongly depend on the presence of other species 
dissolved in the solvent, for example, complex-forming anions (ligands) in 
liquids. Solubility will also depend on the excess (or deficiency) of a common ion 
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(common-ion effect) in the solution. To a lesser extent, solubility will depend on 
the ionic strength of liquid solutions. The last two effects can be quantified using 
the equation for solubility equilibrium. 
There are also a number of less common factors which may affect 
solubility. Solubility may depend on the crystal (or droplet) size of the solute 
phase (typically, solubility will increase with the decreasing crystal size for 
crystals much smaller than 1 μm). For highly defective crystals, solubility may 
increase with the increasing degree of disorder. The last two effects, although of 
great practical importance, are not true solubility effects because true solubility 
occurs at equilibrium, which requires a perfect monocrystal. For substances 
dissolving in an electrochemical reaction, solubility is expected to depend on the 
potential of the solute phase. 
Temperature: 
The solubility of a given solute in a given solvent typically depends on 
temperature. For around 95% of solid solutes, the solubility increases with 
temperature, but gaseous solutes exhibit more complex behavior. As the 
temperature is raised gases usually become less soluble in water, but more 
soluble in organic solvents. 
The chart (graph) shows solubility curves for some typical inorganic salts 
(all solids). Many salts behave like barium nitrate and disodium hydrogen 
arsenate, and show a large increase in solubility with temperature. Some solutes 
(e.g. NaCl in water) exhibit solubility which is fairly independent of temperature. 
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A few, such as cerium(III) sulfate, become less soluble in water as temperature 
increases. This is sometimes referred to as "retrograte" or "inverse" solubility. 
Occasionally, a more complex pattern is observed, as with sodium sulfate, where 
the less soluble decahydrate crystal loses water of crystallization at 32 °C to form 
a more soluble anhydrous phase. 
Organic compounds nearly always become soluble as the temperature is 
raised, in most solvents. The technique of recrystallization, used for purification 
of solids, depends on this difference in solubility in hot and cold solvent. There 
are a few exceptions, such as certain cyclodextrins. 
 
Pressure: 
For condensed phases (solids and liquids), the pressure dependence of 
solubility is typically weak and usually neglected in practice. 
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Henry's law states that the solubility of a gas in a liquid is directly 
proportional to the partial pressure of that gas above the liquid. 
Polarity: 
A popular aphorism used for predicting solubility is "Like dissolves like" 
This indicates that a solute will dissolve best in a solvent that has a similar 
polarity to itself. This is a rather simplistic view, since it ignores many solvent-
solute interactions, but it is a useful rule-of-thumb. For example, a very polar 
(hydrophilic) solute such as urea is highly soluble in highly polar water, less 
soluble in fairly polar methanol, and practically insoluble in non-polar solvents 
such as benzene. In contrast, a non-polar or lipophilic solute such as naphthalene 
is insoluble in water, fairly soluble in methanol, and highly soluble in non-polar 
benzene. 
Liquid solubilities also generally follow this rule. Lipophilic plant oils, 
such as olive oil and palm oil, dissolve in non-polar gasoline (petrol), but polar 
liquids like water will not mix with gasoline. 
Synthetic chemists often use the different solubilities of compounds to 
separate and purify compounds from reaction mixtures. 
Determination of Solubility: 
A. concepts of solubility measurement: 
 Solubility is normally highly dependent on temperature, and so the 
temperature must be recorded for each solubility measurement. Plots of 
solubility against temperature are commonly used for characterizing 
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pharmaceutical solids. Frequently (especially over a relatively narrow 
temperature range), a linear relationship may be given either by Van‟t Hoff plot 
according to  
                             'ln 2 c
RT
a
X sat   
or by a Hildebrand plot according to  
                                             ''lnln 2 cT
R
b
X sat          
Where x2^sat is the mole fraction solubility of the solid solute at an absolute 
temperature T, „a‟ is the apparent molar enthalpy of solution, „b‟ is the apparent 
molar entropy of solution, and c' and c'' are constants. Over a wide temperature 
range (eg. 0-60oC), however, such plots may not be linear. Under such 
circumstances, it may be convenient to fit the solubility-temperature data to the 
following equation: 
cT
R
b
RT
a
X sat  lnln 2  
                                 
Where a, b and c are now adjustable parameters, defined so that „a‟ is the 
apparent enthalpy of the solution at T =0 K, „b‟ is the difference between the 
molar heat capacity of the solute in solution and that of the pure solute and „c‟ is 
a constant. More than three adjustable parameters are rarely necessary and have 
little practical significance. Two general methods are available for determining 
solubility; these can be identified as the analytical method and the synthetic 
method. In the analytical method, the temperature of equilibration is fixed and 
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the concentration of the solute in the saturated solution is determined at 
equilibrium by a suitable analytical procedure. In other words, a saturated 
solution in the presence of an excess of the undissolved solute is prepared at an 
accurately known temperature. This situation may be achieved by suitable 
contact between the undissolved solid and the solvent in a thermostat until 
equilibrium is reached. The analytical method can be subdivided into the 
traditional common batch agitation method and the more recent flow column 
method (also known as the generator column method). In the synthetic method 
the composition of the solute-solvent system is fixed by appropriate addition and 
mixing of the solute and the solvent, and then the temperature at which the solid 
solute just dissolves or just crystallizes is carefully bracketed. Each method 
enables points on the solubility-temperature curve to be determined.  
Solubility determination of solids which are moderately soluble, that is, 
greater than 1 mg/mL (greater than 1 g/L, or greater than 0.1% w/v), normally 
poses no serious problems. However, the direct determination of solubilities 
much less than 1mg/mL, corresponding to very sparingly soluble organic solids, 
is hindered by problems such as (1) slow equilibrium resulting from a low rate of 
dissolution during measurement (2) the influence of impurities (3) the apparent 
heterogeneity in the energy content of the crystalline solid, all of which can lead 
to large discrepancies in reported values. For example, the reported aqueous 
solubilities of griseofulvin at 37oC range from 12.5 to 31.8 mg/L, while those for 
cholesterol range from 0.025 to 2600 mg/mL. 
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B. Common Batch agitation method: 
In the traditional common batch agitation method, the solvent is agitated 
or stirred with a solid solute in a suitable vessel. An aliquot of the saturated 
solution is then removed from the system by centrifugation at the temperature of 
equilibration by filtration, by straining through a plug of glass wool, or even by 
decantation, and it is analyzed by a suitable method. Temperature control better 
than ±1oC is normally essential and should preferably be better than ±0.2oC, 
especially if the solubility is strongly temperature-dependent.  
Equilibration is approached asymptotically at a decreasing rate that 
depends on the volume of the solvent, on the surface area of the solid solute, and 
on the nature and extent of the agitation. The method and time of equilibration 
should be established prior to the solubility determination by measuring the 
dissolved concentration of the solute as a function of time until no further change 
is noted. This approach is known as dynamic solubility study. Analysis at times 
beyond the equilibration time is desirable to verify that a state of true 
equilibrium has been reached. The equilibrium value of solubility may be 
confirmed by agitating a supersaturated solution until its concentration falls to a 
constant value, which should be the same as that obtained on approaching 
equilibrium from the usual under-saturated side. Super-saturation may be 
conveniently achieved by equilibrating the solid solute with the solvent at a 
higher temperature than required for solubility determination. The decreasing 
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concentration vs. time plot from a supersaturated solution should converge with 
the increasing plot obtained from an undersaturated solution.  
It is important to ascertain whether the solid phase of the solute changes 
during equilibration to produce a different polymorph or solvate, by analyzing 
the solid phase (using either chemical or thermal analysis, or x ray diffraction). If 
a solid-solid phase transition occurs during equilibration, the measured 
equilibrium solubility will be that of the new solid phase of the solute. Methods 
of circumventing this problem has been proposed and evaluated.  
Phase separation of the saturated solution from the excess solid solute is a 
critical process. If a filter is employed, it must be inert to the solvent, it must not 
release plasticizers, and its pore size must be small enough to retain the smallest 
particles of the solid solute. Furthermore steps must be taken to monitor, 
minimize and preferably avoid losses of the dissolved solute by adsorption on to 
the filter material and/or on to the vessels, pipettes and syringes. Typically, the 
first small volume of filtrate is discarded until the surfaces of the filter and/or 
vessels are saturated with the adsorbed solute, to ensure that the filtrate analyzed 
has not suffered significant adsorption losses. Adsorption can be a serious 
problem for hydrophobic solutes, for which filtration would not be 
recommended. If decantation or centrifugation is employed for phase separation 
of the saturated solution, any disturbance and carryover of the undissolved solid 
solute (whether precipitated or floating) must be monitored and avoided. 
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C. Synthetic Method: 
For this method, either a weighed amount of the solute (or a definite 
amount of the solvent) is placed in a suitable vessel. While agitating the system 
at constant temperature, known amounts of the solvent (or the solute) are added 
gradually until the solubility limit is reached. Appropriate checks must be 
carried out to ensure that system is very close to equilibrium when the content or 
temperature of the system is recorded. In this method of temperature variation, 
attention is usually focused on the last small crystal. The equilibrium 
temperature is taken as the mean of the two temperatures at which the crystal 
either slowly grows or slowly dissolves. This procedure may also be carried out 
at the micro scale by examining a small volume of the system under a hot-stage 
microscope. 
D. Purity of Solute and analytical implications: 
While the high purity required for individual liquid solvents can be 
obtained relatively easily (therefore presenting few problems), the purity of the 
solid state may often be a questionable property of the sample under study. 
When in solids solution in the solid state, an impurity will alter the crystallinity 
by introducing impurity defects into the crystal lattice, thereby changing the 
thermodynamic and other physical properties of the solid, including the 
solubility and the dissolution rate. Prolonged equilibration of the solid state with 
the saturated solution, however, usually leads to recrystallization of the solute 
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and to a consequent return of the crystallinity and the measured solubility of the 
solid to state to that of the pure, highly crystalline solid. 
When present as a separate phase, the impurity usually, but not 
invariably, exerts only a small influence in the solubility of the solid state of 
interest. However, if the impurity is more soluble than the solute under study, it 
will tend to concentrate in the solution, changing the solvent properties. To 
minimize this effect, the amount of solid in excess of that required to saturate the 
solution should be minimized. 
The purity of the solid solute also has fundamental analytical 
implications. In general, the analytical procedure employed for determining the 
solubility should be specific for the solute of interest. For this purpose, an 
analyte-specific chromatographic method (such as high-performance liquid 
chromatography, HPLC) is preferred.  Such a method will also enable the 
impurities and any possible decomposition products to be identified and 
quantified. 
On the other hand, nonspecific analytical methods (such as liquid 
scintillation counting, spectrophotometry, and titration procedures) may not 
distinguish between the solute under study and certain impurities. When using 
such methods, the solid state of interest should be highly pure and the amount of 
solid in excess of that required to saturate the solution should be minimized. 
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Applications: 
 
Solubility is of fundamental importance in a large number of scientific 
disciplines and practical applications, the most obvious ones being in 
Pharmaceuticals, chemical engineering, material science and geology. 
For example, solubility of a substance is useful when separating mixtures. 
For example, a mixture of salt (sodium chloride) and silica may be separated by 
dissolving the salt in water, and filtering off the undissolved silica. The synthesis 
of chemical compounds, by the milligram in a laboratory, or by the ton in 
industry, both make use of the relative solubilities of the desired product, as well 
as unreacted starting materials, byproducts, and side products to achieve 
separation. 
Another example of this would be the synthesis of benzoic acid from 
phenyl magnesium bromide and dry ice. Benzoic acid is more soluble in an 
organic solvent such as dichloromethane or diethyl ether, and when shaken with 
this organic solvent in a separation funnel, will preferentially dissolve in the 
organic layer. The other reaction products, i.e. the magnesium bromide will 
remain in the aqueous layer, clearly showing that separation based on solubility 
is achieved.  
Polymorphism, solvates and solubility: 
A large number of compounds of pharmaceutical interest are capable of 
being crystallized in either more than one crystal lattice  structure (polymorphs), 
with solvent molecules included in the crystal lattice (solvates), or in crystal 
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lattices that combine the two characteristics (polymorphic solvates). The 
pharmaceutical implications of polymorphism and solvate formation have been 
recognized for some time, with solubility, melting point, density, hardness, 
crystal shape, optical and electrical properties, vapor pressure, and virtually all 
the thermodynamic properties being known to vary with the differences in 
physical form. 
That the crystal structure can have a direct effect on the solubility of a 
solid can be understood using a simple model. For a solid to dissolve, the 
disruptive force of the solvent molecules must overcome the attractive forces 
holding the solid intact. In other words, the solvation free energy released upon 
dissolution must exceed the lattice free energy of the solid for the process to 
proceed spontaneously. The equilibrium solubility of the solid in question 
(which represents the free-energy change of the system) will be determined by 
relative balancing of the attractive and disruptive forces. The balance of these 
forces is determined by the enthalpy change, and the increase in disorder of the 
system (i.e., the entropy change). Since different crystal structures are 
characterized by different lattice energies (and enthalpies), it follows that the 
solubility of different crystal polymorphs (or solvate species) must differ as well. 
It should be emphasized that the solubility differences between polymorphs or 
solvates will be maintained only when a less stable form cannot convert to the 
most stable form. When such conversion can take place, the equilibrium 
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solubility of all forms will approach a common value, namely that of the most 
stable form at room temperature. 
The effect of polymorphism becomes especially critical on solubility since 
the rate of compound dissolution must also be dictated by the balance of 
attractive and disruptive forces existing at the crystal-solvent interface. A solid 
having a higher lattice free energy (i.e.., less stable polymorph) will tend to 
dissolve faster, since the release of a higher amount of stored lattice free energy 
will increase the solubility and hence the driving force for dissolution. At the 
same time each species would liberate (or consume) the same amount of 
solvation energy, since all dissolved species (of the same chemical identity) must 
be thermodynamically equivalent. The varying dissolution rates possible for 
different structures on the same drug entity can in turn lead to varying degrees 
of Bio-availability for different polymorphs or solvates. To achieve 
Bioequivalence for a given drug compound usually requires equivalent crystal 
structures in the drug substance, all though exceptions are known to exist. 
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2.5   Optical Microscopy 
Introduction 
Microscopy is widely used in the pharmaceutical industry for solid state 
characterization of drug substances and products and provides unique 
information about the material such as color, transparency, size, and 
morphology. Morphological evaluation is of extreme importance for 
pharmaceutical solids since the morphology has a great influence over the bulk 
powder properties of the material.  Microscopy is also useful in developing 
preliminary estimations of the particle-size, particle distribution and the relative 
crystallinity of the material.  The term optical microscopy encompasses light 
microscopy, polarizing microscopy, thermal microscopy and chemical 
microscopy.    
Polarized Light Microscopy 
Polarized light microscopy (PLM) is a useful method to generate 
birefringent specimens and to determine qualitative and quantitative aspects of 
the three dimensional crystalline structure.  PLM produces the best images when 
minimum optical elements are used in constructing the objectives.  It is 
important to ensure that lens elements, optical elements, and antireflection 
coatings are free of both strain and birefringent materials that might interfere 
with quantitative assessment of the material‟s birefringence.   
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The polarized microscope is essentially a light microscope that has a 
single vibration direction perpendicular to the propagation direction in contrast 
to ordinary unpolarized light, which consists of a bundle of rays having a 
common propagation direction but different vibration directions.  The 
microscope is equipped with a linear polarizer located below the condenser and 
another polarizer located on top of the eyepiece.  The light from the source is 
rendered linearly polarized by the initial polarizer to conduct the analysis.  The 
polarizer located on top of the eyepiece (the analyzer) is mounted so that its axis 
is orthogonal to that of the initial polarizer.  This orientation of “crossed 
polarizers” does not allow transmitted light to be perceived by the observer.   
Polarized light is produced from ordinary light by reflection or by double 
refraction or absorption with a suitable crystal. Reflected light is almost 
completely polarized and the polarization is dependent on the composition of 
the reflecting surface and on the angle of incidence.  Transparent substances at a 
characteristic angle of incidence may be almost completely effective as polarizers 
with the Brewster angle giving the maximum polarization angle.  In polarization 
by absorption, the transmitted light color observed when analyzing crystals is 
due to light absorption, which varies with the position of the vibration direction.  
Such substances are called pleochroic in which strong absorption occurs in one 
direction and very weak absorption occurs perpendicular to that direction, which 
would transmit white polarized light. In polarization by double refraction, all 
crystals show double refraction except those in the cubic system. Therefore, a 
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light ray incident on a crystal will separate into two components traveling at 
varying velocities and having mutually perpendicular vibration directions. Each 
component is polarized and travels through the crystal at a characteristic velocity 
and at a vibration direction which is perpendicular to the other component.  
  
2.6   Scanning Electron Microscope 
 
The scanning electron microscope (SEM) is a type of electron microscope 
capable of producing high-resolution images of a sample surface. Due to the 
manner in which the image is created, SEM images have a characteristic three-
dimensional appearance and are useful for judging the surface structure of the 
sample. 
Sample preparation 
Materials to be viewed under an electron microscope may require 
processing to produce a suitable sample. The technique required varies 
depending on the specimen and the analysis required. 
Conductive Coating – An ultrathin coating of electrically-conducting 
material, deposited either by high vacuum evaporation or by low vacuum 
sputter coating of the sample. This is done to prevent the accumulation of static 
electric fields at the specimen due to the electron irradiation required during 
imaging. Such coatings include gold, gold/palladium, platinum, tungsten, 
graphite etc. and are especially important for the study of specimens with the 
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scanning electron microscope. Another reason for coating, even when there is 
more than enough conductivity, is to improve contrast. When an osmium coater 
is used, a layer far thinner than would be possible with any of the previously 
mentioned sputtered coatings is possible. 
Due to the loss of information, gold coating has until recently been 
considered a semi-destructive process, as it has not been possible to remove the 
coating without intensive handling, often damaging the specimen; a simple but 
novel technique involving potassium cyanide has recently been reported to 
permit such removal51. 
 
2.7   Powder X-Ray Diffraction 
Uses of X-Ray Powder Diffraction 
The most widespread use of x-ray powder diffraction, and the one we 
focus on here, is for the identification of crystalline compounds by their 
diffraction pattern. Listed below are some specific uses: 
 Identification of single-phase materials – pharmaceuticals, minerals, 
chemical compounds, ceramics or other engineered materials. 
 Identification of multiple phases in microcrystalline mixtures (i.e., rocks) 
 Determination of the crystal structure of identified materials i.e., 
polymorphs. 
 Recognition of amorphous materials or drugs in partially crystalline 
mixtures. 
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An advanced PXRD technique is the Quantitative determination of 
amounts of different phases in multi-phase mixtures by peak-ratio calculations. 
The physics and mathematics describing the generation of monochromatic 
X-rays, and the diffraction of those X-rays by crystalline powders are very 
complex (and way beyond my limited abilities to expound upon them). 
Fortunately a complete understanding of the mathematics involved is not 
required to obtain, interpret and use XRD data. What is required is a basic 
understanding of how the X-rays interact with your specimen, the sources and 
characteristics of possible errors, and what the data tell you about your sample.  
Sample preparation 
The ideal specimen is a statistically infinite amount of randomly oriented 
powder with crystallite size less than 10 μm, mounted in a manner in which 
there is no preferred crystallite orientation. Automated data collection and 
analysis, the preparation of your specimen is usually the most critical factor 
influencing the quality of your analytical data. Sample preparation is a 
significant topic. 
Generate Analytical X-rays 
Copper (Cu) X-ray tubes are most commonly used for X-ray diffraction of  
organic and inorganic crystalline materials. The wavelength of the strongest Cu 
radiation (Kα) is approximately 1.54 angstroms (Å). For most X-ray diffraction 
applications, the closer we can get to monochromatic radiation in our X-ray 
beam, the better our experimental results will be. The radiation produced in the 
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tube includes Kα1, Kα2, and Kβ as the highest energy X-rays and a whole host of 
lower energy radiation. We generally use the Kα for our analytical work. The Kβ 
radiation is usually removed by use of a filter, a monochromator or an energy-
selective detector. The Kα2 radiation is removed from the X-ray data 
electronically during data processing. 
Direct the X-rays at a Powdered Specimen 
An approximately parallel beam of X-rays is directed at the powdered specimen. 
The newest diffractometers with sophisticated (usually of a very 
proprietary nature) optical systems can create a tightly controlled and focused 
incident beam of X-rays. 
Measure X-Rays “Diffracted” by the specimen and obtain a diffraction pattern 
Interaction of X-rays with the sample creates secondary “diffracted” 
beams (actually generated in the form of cones) of X-rays related to interplanar 
spacings in the crystalline powder according to a mathematical relation called 
“Bragg‟s Law”: 
                                                        nλ = 2d sinθ 
where n is an integer 
λ is the wavelength of the X-rays 
d is the interplanar spacing generating the diffraction and 
θ is the diffraction angle 
λ and d are measured in the same units, usually angstroms. For a powder 
specimen in a diffractometer having a statistically infinite amount of randomly 
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oriented crystallites; diffraction maxima (or peaks) are measured along the 2θ 
diffractometer circle. 
The “angle” of the diffraction (recorded as 2θ by convention) is related to 
the interplanar spacing, d, by the Bragg law, and the intensity of the diffraction 
maximum is related to the strength of those diffractions in the specimen. 
The angles and intensities of diffractions are recorded electronically using 
a detector, electronics and specialized software resulting in a plot of 2θ 
(horizontal axis) vs. intensity (vertical axis) for the specimen.  
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CHAPTER III 
EXPERIMENTAL PROCEDURE 
 
3.1   Preparation of Blends  
3.1.1 Materials: 
Acetylsalicylic acid (Aspirin) used in this research was supplied by Sigma 
Chemical Co., St. Louis, MO 63178. Naproxen was obtained from Spectrum 
Chemical, Gardena, CA 90248. Mefenamic acid was obtained from Spectrum 
Chemical, Gardena, CA 90248. A series of different MW PEG was used in this 
research. PEGs of 194, 440, 1470, 8650, 12600, 22000, 23000 MWs were obtained 
from Polymer Laboratories, Shropshire, SY6, UK. PEGs of 3350, 4000, 8000 
molecular weight were obtained from Sigma Chemical Co., St. Louis, MO 63178. 
PEG 8000 is used as a carrier in the preparation of blends. Ethanol 95% was 
obtained from Pharmco Products Inc., Brookfield, CT 06804.   
 
 
 
  49 
3.1.1(A) Acetylsalicylic Acid 
Acetylsalicylic acid is commonly known as salicylate, Aspirin (Lot No. 
129F0112, Sigma Chemical Co., St. Louis, MO 63178) (Fig. 4).  It is used in the 
treatment of mild to moderate pain, fever, and various inflammatory conditions 
such as rheumatic fever, rheumatoid arthritis and osteoarthritis.   Aspirin is also 
used for reducing the risk of recurrent transient ischemic attacks (TIAs) or stroke 
in men who have undergone transient ischemia of the brain due to fibrin platelet 
emboli.  In addition, it is used for reducing the risk of death or nonfatal 
myocardial infarction (MI) in patients who have undergone a previous infarction 
or unstable angina pectoris.  Aspirin also has unlabeled uses for the possible 
effect of long-term aspirin-like analgesics in the prevention of cataract formation, 
used in  conjunction with dipyridamole to prevent MI and stroke and low-dose 
aspirin may aid in the prevention of toxemia of pregnancy and may be favorable 
in pregnant women with inadequate uteroplacental blood flow (systemic lupus 
erythematosus).  
 
Figure 4: chemical structure of aspirin 
Salicylates have analgesic, antipyretic and anti-inflammatory effects.  
Aspirin and other salicylic acid derivatives are hydrolyzed to salicylic acid.  The 
  50 
pharmacological effects of salicylates involve lowering elevated body 
temperature through vasodilation of peripheral vessels, thereby enhancing 
dissipation of excess heat.  The analgesic and anti-inflammatory effect may be 
mediated through prostaglandin synthetase enzyme complex inhibition.  Aspirin 
also irreversibly inhibits platelet aggregation through acetylation of platelet 
cyclo-oxygenase, which prevents synthesis of the prostaglandin derivative 
thromboxane A2, a potent vasoconstrictor and inducer of platelet aggregation 
and platelet release reaction.   
Aspirin exists as white crystals, commonly tabular or needle-like, or a 
white, crystalline powder and is odorless or has a faint odor.  It is stable in dry 
air and gradually hydrolyzes to salicylic and acetic acids in moist air.  It melts at 
about 135°C.  One gram of aspirin is soluble in 300 mL water, 5 mL alcohol, 17 
mL chloroform, and from 10 to 15 mL ether.   
The normal oral adult dose is 325 to 650 mg every 3 to 4 hours as needed 
and a low dose of 81 mg is also available.  Salicylates are rapidly and completely 
absorbed after oral administration.  Bioavailability depends on the dosage form, 
presence of food, gastric emptying time, gastric pH, presence of antacids or 
buffering agents and particle size.  Peak plasma levels are reached within 2 hours 
after oral administration with fairly constant levels maintained for 4 to 6 hours.  
Adverse effects are infrequent, but the most common ones are related to 
gastrointestinal disturbances (dyspepsia, nausea, vomiting, and occult bleeding). 
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3.1.1(B) Naproxen 
Naproxen (Lot SF0468, Spectrum Chemical, Gardena, CA 90248) (Fig. 5) is 
a member of the Non-Steroidal Anti inflammatory Drug family.  It is used for the 
relief of mild-to-moderate pain and for the treatment of primary dysmenorrheal, 
rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, tendonitis, bursitis, 
acute gout, and juvenile arthritis.  It is also available over-the-counter for the 
temporary relief of minor aches and pains associated with the common cold, 
headache, toothache, muscular aches, backache, minor arthritis pain, pain of 
menstrual cramps, and reduction of fever. 
 
 
Figure 5:   Chemical structure of naproxen 
Naproxen is selective for COX-1.  It is an off-white crystalline powder 
with a bitter taste.  It melts around 155°C.  Naproxen is practically insoluble in 
water at pH 2, freely soluble in water at pH 8 or above and sparingly soluble in 
alcohol.   
Naproxen is available in tablets containing 250, 375, and 500 mg.  The 
normal adult dose for ankylosing spondylitis is 250 to 375 mg twice daily and 
increased or decreased according to the patient.  It appears to be completely 
absorbed after oral administration with peak plasma levels reached within 2 to 4 
. 
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hours although the naproxen sodium form is more rapidly and completely 
absorbed than the naproxen formulation. 
3.1.1(C) Mefenamic Acid  
Mefenamic acid (Lot SF1673, Spectrum Chemical, Gardena, CA 90248) 
(Fig. 6) is an analgesic used in the relief of mild-to-moderate pain and primary 
dysmenorrhea.  It is a white to off-white, crystalline powder and melts between 
227 and 232°C.  It is insoluble in water and one gram is soluble in 220 mL alcohol.  
 
Figure 6:   Chemical structure of mefenamic acid 
 
3.1.1(D) Polyethylene glycol 8000 
Polyethylene glycol 8000 (Batch 013K0063, Sigma, St. Louis, MO 63103) 
(Fig. 7) is used as a carrier in the preparation of many drugs and eutectics.  It is a 
white, waxy solid at room temperature and is soluble in water and many organic 
solvents.  It melts between 56 and 63°C.    
n
CH 2 CH 2HO O H
 
 
Figure 7:   Chemical structure of polyethylene glycol 
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3.1.1(E) Ethanol 
Ethanol 95% (Cas No. 64-17-5, Pharmco Products Inc., Brookfield, CT 
06804) is an aliphatic alcohol.  It is a clear, colorless liquid with a pleasant smell 
and it melts at -117.3°C and boils at 78.5°C.  It is completely miscible in water and 
has a specific gravity of 0.79.  Ethanol burns in air with a blue flame, forming 
carbon dioxide and water.  
 
3.1.2 Methods of Preparation 
3.1.2(A)   Fusion Method or Melting Method 
In the fusion method, the blend is prepared by heating a mixture of a drug 
and a water soluble carrier to a temperature above the eutectic point until it 
melted.  The mixture was then constantly stirred in an ice bath to cool and 
rapidly solidify.  The drug became dispersed in the carrier matrix, resulting in a 
reduction of the particle size.  The mass was then crushed, pulverized, and 
sieved.  A solid solution would form if the drug is highly soluble in the carrier, 
where the drug could remain dissolved in the solid state.  This results in greatly 
enhanced dissolution rates.  On the other hand, if the drug is not highly soluble 
in the carrier, only a slight increase in dissolution would occur since crystallites 
of the drug become dispersed in the carrier.   
Variations have been made to the fusion method to optimize the 
dispersion of the drug in the carrier matrix. The cooling process can be 
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accelerated by using stainless steel plates or by spraying the hot melt onto a cold 
metal surface. 
Limitations of the fusion method include the miscibility of the drug in the 
carrier and the thermal stability of both components.  High temperatures may 
cause decomposition or evaporation of the drug.  Precautions may be taken to 
avoid oxidation by preparing the solid dispersion in an inert atmosphere or 
avoiding evaporation by preparing it in a closed system.  Therefore, 
temperatures just above the eutectic point are recommended.   
3.1.2(B)   Solvent Method   
In the solvent method, the blends are prepared by dissolving both the 
drug and the carrier in a suitable solvent and evaporating the solvent on a hot 
plate and/or under vacuum.  Temperatures in the range of 23-65°C are required 
for removal of solvents.  Super saturation occurs as the solvent is being removed, 
followed by precipitation of the constituents resulting in a solid residue.  The co 
precipitate, a dispersion prepared by the solvent method, is then dried under 
vacuum to ensure complete removal of the solvent.  Solvent removal may also be 
accomplished by freeze drying or by spray-drying.     
Limitations of the solvent method include the reproducibility of 
crystalline forms and the choice of a suitable solvent.  Both the drug and the 
carrier must be soluble in the solvent and thorough removal must be attained 
since most organic solvents have toxicity issues.  Also, when organic solvents are 
used, minor variations in the conditions may lead to large changes in product 
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performance.  An economic limitation arises when large volumes of solvent are 
required for dissolution of the drug and the carrier.   
Advantages of the solvent method include preparation of solid 
dispersions for thermolabile substances because of the low temperature required 
for evaporation of the solvent.  Also, polymers with high melting points could be 
considered an option for use as a carrier.     
3.1.2(C)   Fusion-Solvent Method 
The fusion-solvent method involves melting the carrier to the liquid form, 
and incorporating the drug, which has been previously dissolved in a suitable 
solvent, into the carrier melt.  Limitations associated with this method include 
complete evaporation of the solvent due to toxicity reasons, the selected solvent 
or dissolved drug may not be miscible with the polyethylene glycol melt, and it 
is limited to drugs with low therapeutic doses.  Advantages of this method 
include its suitability for drugs with high melting points and those that are 
thermolabile.     
 
 
3.1.3 Method Used: 
 
The solvent method was used in the formation of all blends.  Both the carrier 
and the drug were weighed in various compositions and combined in a beaker.  
Both components were dissolved in about 5 mL ethanol. The mixture was heated 
on low on a hot plate to allow evaporation of the solvent, not exceeding 65-70°C.  
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The resulting mass was then dried at room temperature in a vacuum for 2 hours 
and stored in a dessicator for 24 hours to ensure complete evaporation of the 
toxic solvent.  The mixtures were then stored at -20°C for 4 days to ensure 
complete crystallization.  The solid residue was finally ground to fine particle 
size with a mortar and pestle for evaluation by DSC, DEA. 
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3.2 Preparation of Polymorphs 
3.2.1 Materials: 
Tolbutamide (Lot No. T0891) used in this research was supplied by 
Sigma-Aldrich Co., St.Louis, MO 63178. Nifedipine (N7634) was obtained from 
Fisher Scientific, Fair Lawn, NJ. Acetonitrile solvent (Lot No. 0043 KAPM) was 
obtained from Mallinckrodt Baker Inc., Phillipsburg, NJ. Solvents 1-Octanol and 
1,4-Dioxane were obtained from Sigma-Aldrich Co. , St. Louis, MO 63103. Liquid 
Nitrogen was used for Quench cooling during the preparation of amorphous 
polymorphs of Nifedipine.   
 
3.2.1(A) Tolbutamide: 
Tolbutamide is an oral blood-glucose lowering drug of the sulfonylurea 
class. It was historically developed as part of the sulfanilamide family of 
compounds and has been utilized in diabetes research. Tolbutamide has been 
used in a cDNA micro array assay to probe changes in gene expression in HepG2 
cells upon their administration. It has been utilized to counteract insulin activity 
in a patch-clamp investigation of ATP-sensitive K+ channels in mouse pancreatic 
β-cells. Tolbutamide is a pure, white, crystalline compound which is practically 
insoluble in water with a molecular weight of 270.35gm which melts at 129oC. 
The chemical name of Tolbutamide is benzene-sulfonamide, N-[(butyl amino)-
carbonyl]-4-methyl. Its structure can be represented as follows:  
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 Figure 8: Chemical structure of Tolbutamide 
Tolbutamide exists in four polymorphic forms: Form I, Form II, Form III 
and Form IV. Our focus is on a Form “Pure”, Form I (A) and Form III (B). 
Polymorph A, crystallized from acetonitrile, was identified as Form I. Polymorph 
B, crystallized from 1-octanol was identified as Form III.  
3.2.1(B) Nifedipine: 
Nifedipine is a dihydropyridine L-type voltage sensitive calcium-channel 
blocker with peripheral and coronary vasodilator properties. Its mode of action is 
at the slow channel where it inhibits calcium ion influx into the cells. In the heart, 
nifedipine as well as verapamil and diltiazem depress cardiac contractions and 
heart rate. It is reported that nifedipine exerts part of its physiological actions 
through potentiation of adenosine, an endogenous calcium channel blocker, and 
suggest that nifedipine may act through a mechanism much more complex than 
simple calcium channel blockade. Nifedipine is a yellow crystalline compound 
which is practically insoluble in water with a molecular weight of 346.30gm 
which melts at 172oC. The chemical name of nifedipine is dimethyl-2,6-dimethyl-
4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate. Its structure can be 
represented as follows:  
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                                      Figure 9: Chemical structure of Nifedipine 
 
 
3.2.1(C) Acetonitrile: 
Acetonitrile 99% is a clear, colorless liquid, which melts at -48°C and boils 
at 82°C.  Its density is 0.786 g/mL at 25°C. It is used to prepare a polymorph of 
tolbutamide.    
3.2.1(D) 1-Octanol: 
1-Octanol 99% naturally occurs in the form of esters. The primary use of 
octanol is in the manufacturing of various esters. It is immiscible with water. 1-
Octanol melts at -15°C and boils at 196°C. It has a density of 0.827 g/mL at 25°C. 
In this research it is used to prepare a polymorph of tolbutamide.  
3.2.1(E) 1, 4-Dioxane: 
1, 4-Dioxane, often called dioxane, is a clear, colorless heterocyclic ether 
organic compound which is a liquid at room temperature and pressure. It has the 
molecular formula C4H8O2 and a boiling point of 101°C. It is commonly used as 
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an aprotic solvent. 1,4-Dioxane has a weak smell similar to that of diethyl ether. 
In this research it is used to prepare a polymorphic form of nifedipine. 
 
3.1.2 Method of Preparation 
3.2.2(A) Tolbutamide A 
1 gm sample dissolved in 2 mL of acetonitrile & heated to 60°C .The 
resulting solution was cooled and then filtered and vacuum dried for a week.  
3.2.2(B) Tolbutamide B 
Crystallization from 1-Octanol was done as follows, 1 gm sample 
dissolved in 2 mL of 1-octanol & heated to 60°C .The resulting solution was 
cooled and then filtered and vacuum dried for a week.  
3.2.2(C) Nifedipine pseudo Amorphous 1 (Form B) 
Approximately 2g of Nifedipine raw material was placed on a thick 
aluminum sheet. It was then heated at an approximate heating rate of 10C/min 
on a hot plate until the sample melted at 173C. The molten sample was 
transferred to a metal vessel containing liquid nitrogen, as soon as it reached the 
melting temperature. The sample was kept in liquid nitrogen for 4-5 minutes. A 
glassy substance was obtained. The amorphous material was used as prepared. 
3.2.2(D) Nifedipine pseudo Amorphous 1 Pulverized (Form B) 
Approximately 2g of Nifedipine raw material was placed on a thick 
aluminum sheet. It was then heated at an approximate heating rate of 10C/min 
on a hot plate until the sample melted at 173C. The molten sample was 
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transferred to a metal vessel containing liquid nitrogen, as soon as it reached the 
melting temperature. The sample was kept in liquid nitrogen for 4-5 minutes. A 
glassy amorphous material was obtained and pulverized using a mortar and 
pestle. 
3.2.2(E) Nifedipine pseudo Amorphous 2 (Form B) 
Approximately 2g of Nifedipine raw material was placed on a thick 
aluminum sheet. It was then heated at an approximate heating rate of 10C/min 
on a hot plate until the sample melted at 173C. The molten sample was 
transferred to a metal vessel containing liquid nitrogen, as soon as it reached the 
melting temperature. The sample was kept in liquid nitrogen for 4-5 minutes. A 
glassy substance was obtained. The amorphous material was used as prepared or 
pulverized using a mortar and pestle with the addition of liquid nitrogen 
(cryogenic grinding). 
3.2.2(F) Nifedipine Solvate (Form C) 
Approximately 2 g of Nifedipine powder was added to 50 mL 1,4-dioxane 
while stirring until a saturated solution was obtained. The solution was left at 
room temperature in a rated hood to slowly evaporate for approximately 4 days. 
The recrystallized material was removed from the solvent using a spatula and 
dried on filter paper to ensure evaporation of surface solvent molecules.  
3.2.2(G) Nifedipine Solvate Pulverized (Form C) 
Approximately 2 g of Nifedipine powder was added to 50 mL 1,4-dioxane 
while stirring until a saturated solution was obtained. The solution was left at 
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room temperature in a rated hood to slowly evaporate for approximately 4 days. 
The recrystallized material was removed from the solvent using a spatula and 
dried on filter paper to ensure evaporation of surface solvent molecules. The 
obtained material was pulverized using a mortar and pestle. 
 
3.3   Analytical Techniques 
3.3.1 Differential Scanning Calorimetry 
The TA Instruments robotic Q2000 DSC was used to determine the 
thermal transitions of the excepient PEG, PEG blends and polymorphs with the 
mass of the samples ranging from 2 to 7 mg.  
Different MWs of PEG were scanned from -60 to 260oC in a HCHCH  
technique, at a heating rate of 10oC/min in nitrogen with a closed crimped 
aluminum pan and lid. 
PEG/Drug blends were scanned from 0 to 300ºC at a heating rate of 
10ºC/min in nitrogen with a closed crimped aluminum pan. 
The polymorphs of tolbutamide and nifedipine were scanned from 0 to 
200oC in a HCHCH technique, at a heating rate of 10oC/min in nitrogen with a 
closed crimped aluminum pan and lid. 
 
3.3.2 Dielectric Analysis 
A 2970 DEA, TA Instruments, was used to measure the dielectric 
properties of the blends and the polymorphs of Nifedipine and Tolbutamide. 
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Each sample was examined in a heat-cool-heat cycle at 5oC/min in dry nitrogen. 
Only the heat cycle was recorded by the DEA instrument. The procedure used 
AC frequencies of 0.1, 0.5, 0.8, 1.0, 5.0, 10, 50, 100, 500, 800, 1000, 5000 and 10000 
Hz. The sample size was ca. 20 mg on an interdigitated single surface gold 
ceramic electrode.  The electrode was ca. 4 cm2 surface area and ca. 0.1 mm 
spacing between the tines of the interdigitated electrode. The temperature range 
for each chemical was determined by their DSC curve, that is, the starting 
temperature at 40oC and then heated to ca. 30oC above the endothermic peak 
melting temperature.  The resulting data collected was the temperature, 
frequency (Hz), loss factor (e”), the electrical conductivity (i.e., the frequency x e” 
x constant), permittivity (e‟), and tan delta (tan δ) (i.e. e”/e‟). 
A digital, Konica-Minolta camera with 20-80 mm macro lens was used to 
characterize the crystalline and amorphous materials on the single surface 
interdigitated array gold electrodes. 
 
3.3.3 Scanning Electron Microscopy 
Philips XL 30 SEM was used to obtain the photomicrographs of the 
various polymorphic crystal forms. 
The samples were adhered to a piece of carbon tape on a metal stub, 
coated under vacuum with carbon and then coated with a thin gold-palladium 
film. The samples were examined at 350X and 1000X. 
 
  64 
3.3.4 Powder X-ray Diffraction 
PXRD analyses were performed using a one piece, Bakelite well mount 
and a Bragg-Brentano configuration. The drugs and polymorphs were examined 
with Copper K alpha radiation with a wavelength () =1.5406 A°; voltage, 40KV 
and 35 mA. The values were obtained at a scan rate of 2° 2θ/min. d-spacing 
values (Ǻ) and the correlating relative intensities were generated for each 
sample. 
3.3.5 FT Infrared Spectroscopy 
Galaxy Series FT-IR 4020 was used for scanning the polymorphs. The 
samples were prepared by using a mulling technique. 
Procedure 
Place about 15-20 mg of polymorph in a clean dry polished mortar. Grind 
the sample with vigorous motion.  Restrict the sample to the bottom of the 
mortar as much as possible.  Continue grinding until the sample becomes a dry 
powder (Ideally, the solid should consist of particles less than 100 m in 
diameters, although this may be difficult to discern them without the aid of a 
microscope).  For particularly hard samples, a second wet grinding may be 
necessary.  When ground, add a small drop of paraffin oil to the mortar.  Grind 
the sample until all the material is suspended in the mulling agent.  It may be 
necessary to add an additional drop of mulling agent as the grinding is 
continued.  The ideal consistency is about that of Vaseline.  Place some of the 
mull on a NaCl plate.    Place a second plate on top of the mull and move the 
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plates to spread the mull evenly between the plates.  The mull should appear 
slightly translucent.  Clamp the plates in a demountable cell and record the 
spectra.  If the absorption bands are too strong, the mull may be thinned by 
tightening the mounting screws or removing some of the mull from between the 
plates.  If the spectra appear distorted, the grinding process was not satisfactory 
and should be repeated with fresh materials.  Run a spectrum of paraffin oil and 
subtract it from the mull spectra. Use CCl4 to clean the NaCl plates before and 
after running each sample.  
3.3.6 Solubility 
A classical solubility method was used to evaluate the polyethylene 
glycols in water and polymorphs in Ethanol- Water blends.  
A given amount of PEG was dissolved in specified amount of water for 
about 1 hour and the supernatant is discarded and the residue is weighed to 
determine the solubility % by weight. 
Different concentrations of ethanol-water blends were prepared by mixing 
ethanol in water. The concentrations prepared were 65/35, 75/25, 85/15 of 
ethanol/water. In a 1.5mL centrifuge vial, a given amount ca. 30mg of 
polymorph samples were dissolved in various concentrations of ethanol-water 
blends. It is centrifuged after 30 minutes, for 2 minutes at 4000 rpm. The 
supernatant was separated. The solid pellet left in the vial was dried by using a 
fast dryer and weighed to determine the solubility percentage by weight. 
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3.3.7 Optical microscopy 
An Olympus BX60 microscope and Olympus U-TVIX Hamamatsu chilled 
CCD camera model C5985 along with Metamorph (Metaimaging Series) software 
were used to capture black and white photographic digital images of  excipients, 
blends and polymorphs of tolbutamide and nifedipine at 10x optical and 40x 
objective lens magnification. The samples were prepared by placing a small 
amount ca. 2-3mg of drug on a glass slide and making a thin dispersion on the 
slide surface using a clean flat spatula. The prepared slides are kept on the 
microscope stage and the structural morphology pictures of the drugs are 
captured by Olympus U-TVIX Hamamatsu chilled CCD camera model C5985, 
operated by Metamorph (Metaimaging Series) software.  
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CHAPTER IV 
 
RESULTS AND DISCUSSION 
 
4.1   Polyethylene Glycol Molecular Weight  
 
The results of this study are summarized in Figures 10-12. The thermal 
properties for 3 MWs (1470, 8000 and 23000) are examples and summarized in 
Table II and Table III. A summary of the melting peak temperature (Tmp), heat of 
fusion (∆Hf), crystallization peak temperature (Tcp) and heat of crystallization 
(∆Hc) are collected in Table III. ΔΔH is a measure of the difference of ΔHf – ΔHc.  
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Figure 10: Heat-Cool-Heat-Cool-Heat Data for PEG 23000 
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Figure 11:  Heat-Cool-Heat-Cool-Heat Data for PEG 8000 
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Figure 12:  Heat-Cool-Heat-Cool-Heat Data for PEG 1470 
 
Tables II and III summarize the data for nine different molecular weights 
from 440 to 23000. The Tmp, increases with the MW and levels off at 63-65ºC. The 
Tcp increases with the MW and levels off at 41-42ºC.  
 
Table II:  Effects of Molecular Weights of PEG on Melting and Crystallization Properties for         
                      PEG 1470, 8000 and 23000 
 
Cycle PEG 1470 PEG 8000 PEG 23000 
Tmp (ºC) 47 61 64 
∆Hf (J/g) 126 136 47 
    
Tcp (ºC) 29 42 42 
∆Hc (J/g) 123 132 44 
    
ΔT 18 19 22 
ΔΔH 3 4 3 
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Table III:  Summary of average values for all PEG Molecular Weights 
 
Molecular 
Weight 
Average Values 
% 
Crystallinity 
 
Tmp 
(ºC) 
∆Hf 
(J/g) 
Tcp 
(ºC) 
∆Hc 
(J/g) 
 
440 -4 65 -30 51 42% 
1470 47 128 32 123 85% 
3350 59 105 36 95 70% 
4000 59 152* 38 143 100%* 
8000 61 137 42 133 90% 
8650 63 132 42 126 86% 
12600 63 86 41 81 56% 
22000 65 116 42 110 76% 
23000 64 47 42 44 31% 
                    * Assume max value, 152 J/g = 100 % crystallinity 
 
Assuming that the heat of fusion for PEG 4000 with the maximum value 
of 152 J/g is 100% crystalline, then we can ratio this value with other heats of 
fusion and can determine a relative percent crystallinity (see Table III). It is 
interesting to note that PEG 8000 is calculated to be 90% crystalline and by a 
second method, DEA, it is 82% crystalline10 (see Figure 13) 
 
 
 
                          Figure 13:  Dielectric Analysis of Semi-crystalline PEG 8000: 82% crystalline 
 
The repeatability of this percent crystallinity can be viewed by comparing 
PEG 8000 and PEG 8650 which are 90% and 86% respectively. Above the 
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%crystallinity for PEG 4000, we note that the percent crystallinity decreased with 
increase in MW from 4000 to 23000. However, the melting peak temperature 
(Tmp) for the series is from 64-69ºC. The highest MW, 23000 at 31% relative 
crystallinity is anticipated since it is well known that the higher MW polymers 
are less crystalline and more amorphous. The degree of super cooling (ΔT) that is 
the Tmp-Tcp (peak melting temperature – peak crystalline temperature) increases 
with increase in MW (see Table II).  
The effect of PEG MW on Tm (ºC) can be seen in Figure 14. There is a good 
correlation of the average melt temperature and the log of its MW fitted with a 
polynomial curve fit and an R2= 0.99 for literature values.  
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                 Figure 14:  Effects of PEG Molecular Weight (Literature) vs. Melt Temperature (Tm) 
 
The effect of MW in this study also had a good correlation between the 
average DSC Tmp and the log molecular weight of PEG fitted with a polynomial 
with an R2 = 0.973 (see Figure 15). 
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           Figure 15:  Effects of Molecular Weight of PEG on the DSC Peak Melting Temperature (Tmp) 
 
The effect of molecular weight on the DSC Tcp (Figure 16) appears to show 
a correlation but is limited in that most of the Tcp data is from 31 to 41. 
Additional studies are needed to confirm the relationship in Figure 16. The 
degree of super cooling for PEG increases with increase in molecular weight 
from 15ºC for PEG 440 to 23ºC for PEG 23000 (see Figure 17).  
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           Figure 16:  Effects of Molecular Weight on the DSC Peak Crystallization Temperature (Tcp) 
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                  Figure 17:  Effects of PEG Molecular Weight on the Degree of Supercooling (ΔT) 
 
 
 
The solubility of the PEGs in water at 25ºC and pH 7 was determined. The 
solubility decreased with increasing molecular weight (see Figure 18). 
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                        Figure 18:  Effects of PEG Molecular Weight on Solubility 
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4.2   Polyethylene Glycol on the Crystallinity of Drugs 
The first set of drug and PEG 8000 excepient was Aspirin/PEG. The DSC 
curves for Aspirin and PEG are given in figure 19. The melting curve for PEG 
8000 revealed the melting from Tm of 59 to 63oC with a ΔHf, of 154 J/g. The 
aspirin DSC curve melting was Tm 139 to 144oC and a ΔHf 126 J/g, see Figure 19. 
A (10/90) w (Aspirin/PEG) blend had a Tm of 54-61oC and ΔHf 172 J/g, Figure 
20. In a (10/90) w blend one expects the ΔHf to be 90% of 154 J/g or 139 J/g. The 
observed difference between measured and expected ΔHf was a 24% increase. 
This enhanced crystallization is interpreted as the crystallization of PEG with the 
amorphous aspirin co-crystallizing epitaxially to a different crystal habit. The 
morphology of PEG 8000 at 100X magnification with a polarizing microscope 
was tubular structures, which are typically 110 X 380 microns (see figure 21). The 
aspirin crystal form was logs and platelets, typically 150 x 620 microns (see figure 
22). The (10/90) w (Aspirin/PEG) blend had microscopic irregularly shaped 
crystals averaging 43-130 microns (see figure 23). The DSC property and 
microscopic structure results suggest the blend is a new physical form for this 
formulation.  
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Figure 19: DSC of Pure Aspirin (Tm = 138
o
C) and PEG (Tm = 59.0
o
C) 
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Figure 20: DSC of a (10/90) w Blend of Aspirin and PEG (only Tm = 54-61
o
C) 
 
 
 
   20mm=200μ 
 Figure 21: Photo microscopic picture of PEG Pure crystals 
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  20mm=200μ 
 Figure 22: Photo microscopic picture of Aspirin Pure crystals 
 
 
20mm=200μ 
Figure 23: Photo microscopic picture of (10/90)w Blend of Aspirin and PEG       
crystals 
 
The second drug, Mefenamic Acid, MEF, and PEG 8000 blend, (10/90)w, 
was evaluated by DSC, Figure 24. The Tm was 59-63oC and ΔHf 158 J/g. The 
observed difference between measured and expected ΔHf was a 14% increase. 
This enhanced crystallization of PEG with the MEF produced a different crystal 
habit for this blend also. The DSC of the third drug blend (25/75)w of Naproxen 
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with PEG 8000 is Figure 25. The Tm is 54-59ºC and ΔHf 141J/g. In a (25/75)w 
blend one expects the ΔHf to be 75% of 154 J/g or 115 J/g. The observed 
difference between measured and expected ΔHf was a 23% increase. This 
increase is apparently due to the co-crystallization of Naproxen with PEG 8000. 
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Figure 24:  DSC of a (10/90) w Blend of MEF and PEG (only Tm = 59-63
o
C) 
 
 
              
54.41°C
141.3J/g
4.82°C
2.14min
58.88°C
-25
-20
-15
-10
-5
0
H
e
a
t 
F
lo
w
 (
m
W
)
0 50 100 150 200 250 300
Temperature (°C)
Sample: NAP/PEG 25/75
Size:  4.8000 mg
Comment: HEAT  HERMETICALLY SEALED
DSC
File: C:...\DSC\raj\TABLE\NAPPEG2575.H.001
Operator: RAJ
Run Date: 17-Apr-2007 13:16
Instrument: DSC Q2000 V23.5 Build 72
Exo Up Universal V4.3A TA Instruments
 
Figure 25:  DSC of a (25/75) w Blend of Naproxen and PEG (only Tm = 54-59
o
C) 
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To understand this structural modification, the drugs and PEG were 
examined by DEA and compared the DSC curve and the electrical conductivity 
curve together. The DEA and DSC of Aspirin are seen in Figure 26. The DEA 
conductivity for crystalline aspirin was 0.22 pS/cm while the amorphous liquid 
conductivity was 177,000 pS/cm. The crystalline phase conductivity was 6 orders 
of magnitude lower than the amorphous phase. There was a good correlation 
between the DSC melt profile and the DEA conductivity profile. Aspirin melted 
and decomposed as observed by the DSC and DEA curves. The DEA overlay on 
the DSC of PEG 8000 revealed that the crystalline phase is probably composed of 
amorphous and crystalline components, Figure 27. This is based on the observed 
conductivity typically 1 pS/cm for PEG where most other 100% crystalline 
phases have conductivity of 10-2 to 10-1pS/cm. The DEA/DSC curve of the 
(10/90)w blend of aspirin/PEG is presented in Figure 28. The conductivity for 
this blend changed significantly from the onset of melting (662 pS/cm) to the 
amorphous liquid (274,000 pS/cm). Clearly the conductivity is differentiating the 
amorphous blend from the crystalline blend. There is an obvious linear increase 
in conductivity prior to the melting in this study as defined by the DSC curve, 
i.e., 8-25ºC below the Tmp11.    
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            Figure 26:  DSC and DEA of Aspirin. Aspirin melts and degrades >160
o
C. 
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            Figure 27:  DSC and DEA of PEG 8000. PEG is semi-crystalline.  
 
  80 
           
56.15°C
661.7pmho/cm
10.Hz
70.70°C
273597pmho/cm
10.Hz
61.44°C
-11.75mW
54.35°C
172.1J/g
5.74°C
-15
-10
-5
0
5
[ 
  
  
  
  
  
  
] 
H
e
a
t 
F
lo
w
 (
m
W
)
 –
 –
 –
 –
 
10
100
1000
10000
1.0E5
1.0E6
Io
n
ic
 C
o
n
d
u
c
tiv
ity
 (
p
m
h
o
/c
m
)
20 40 60 80 100 120 140 160 180
Temperature (°C)
                  DEA asa/peg.10.90–––––––
                  DSC asa/peg.10:90– – – –
DEA  AND DSC ASA/PEG (10/90)
Exo Up Universal V4.3A TA Instruments
 
Figure 28: DSC and DEA of a (10/90) w Blend of Aspirin and PEG (only Tm = 54-                
61
o
C) 
 
 
The crystalline to amorphous transition is presented in Figure 29. PEG 
8000 was examined by DEA heating the sample, air cooling it and reheating it 
four times, Figure 29. The 1st run onset of conductivity was 11pS/cm for the 
crystalline phase rising continuously to 65,000 pS/cm for the amorphous melt. 
There is no apparent transition from solid to liquid for this curve. The 4th run 
onset of conductivity was 2,700 pS/cm also increasing to ca. 65,000 pS/cm for the 
melt. Based on a comparison of the log conductivity at 46ºC, 17ºC below the DSC 
melting temperature, to the total conductivity change at 46ºC from the crystalline 
curve to the amorphous extrapolated curve the 4th sampling of PEG contains 32% 
crystalline and 68% amorphous material. Aspirin DEA conductivity varied from 
7.3 pS/cm at 110ºC to 142,000 pS/cm at 147ºC, Figure 30. There was again no 
obvious transition at the DSC melt temperature of 144ºC. However, there was a 
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very linear conductivity vs. temperature profile for this drug from 109-147ºC. We 
have observed a mechanical transition in the same range of temperature by 
Thermal Mechanical Analysis (TMA) and have titled this event as a dielectric 
visco-elastic transition. The 2nd run of aspirin by DEA had a rapid rise of 
conductivity from 40 to 62ºC with a conductivity of 126 pS/cm, then decreasing 
with temperature to 87ºC as an indication of dehydration of a moist sample. The 
co-crystallized (10/90)w blend of aspirin and PEG 8000 was examined in a heat 
cool heat cool heat cycle, i.e. heating three times. The amorphous phase 
conductivity was 394,000-554,000 pS/cm, while the original crystalline phase 
conductivity was 628 pS/cm. The 2nd and 3rd samplings were not a pure 
crystalline blend but semi-crystalline based on their resulting conductivity 
values, Figure 31.  
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Figure 29: DEA of PEG 1
st
 Heat, Cool offline, & 4
th
 Reheat (note DSC Tm = 59-63
o
C) 
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Figure 30: DEA of pure Aspirin 1
st
 and 2
nd
 Run (note DSC Tm = 138-144
o
C) 
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Figure 31: DEA of a (10/90) w Blend of Aspirin and PEG (note DSC Tm = 54-61
o
C). 
Three DEA samplings of the (10/90) w Blend. Heat, slow cool off line and reheat (twice).  
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Table IV:  Summary of the observed and literature DSC melt values. 
 
 
 
The symbols used in the tables below include  
Tm = the melt temperature or the extrapolated onset temperature. 
Tp = DSC peak temperature 
TO = Onset temperature of electrical conductivity change and increase 
TA= Temperature where the sample is at its highest conductivity (typically        
>100,000 pS/cm) in the amorphous (melt) phase. 
 
 
 
DRUG 
OBSERVED LITERATURE 
Melting Temperature Heat of  
Fusion(J/g) 
Melting Temperature Heat of  
Fusion(J/g) Tm (
 o
C ) Tp (
 o
C ) Tm (
o
C ) Tp (
 o
C ) 
 
Indium 
 
Vanillin 
 
Aspirin Pure (ASA) 
 
Polyethylene Glycol 
(PEG) 
 
Blend ASA/PEG 
(10/90)w% 
 
Blend MEF/PEG 
(10/90)w% 
 
Blend NAP/PEG 
(25/75)w% 
 
156.6 
 
82 
 
138 
 
59 
 
 
54 
 
 
59 
 
 
54 
 
158.5 
 
84 
 
144 
 
63 
  
 
61 
 
 
63 
 
 
59 
 
28.7 
 
149 
 
126 
 
154 
 
 
172 
 
 
158 
 
 
141 
 
157 
 
82 
 
138 
 
56-61 
 
 
_ 
 
 
_ 
 
 
_ 
 
159 
 
84 
 
140 
 
63-65 
 
 
_ 
 
 
_ 
 
 
_ 
 
28.4 
 
148 
 
_ 
 
155-192 
 
 
_ 
 
 
_ 
 
 
_ 
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The DSC and DEA properties are found to be accurate based on the 
melting characteristics of USP Vanillin and Indium, see Table IV. The indium 
calibration of the DSC proved the melting and heat of fusion measurements are 
correct. The DSC properties of pure Aspirin and PEG 8000 were in good 
agreement with literature values, see Table IV. The three drug blends only had 
melting temperatures associated with PEG, Table IV. The higher than expected 
heat of fusions for the blends signifies co-crystallization of the amorphous drug 
with PEG. A comparison of the DSC and DEA results clearly indicate that the 
ASA/PEG (10/90)w drug melted in the same range as pure PEG, compare blend 
Tm 54-61ºC vs. 59-63ºC. In any of the low drug dose blends the melting of the 
drug was not observed which indicates that the drug is amorphous. There is a 
good correlation between the DSC TP of the pure PEG, Aspirin and blend and the 
DEA TA, see table V. Both TP and TA represent the state of the material in that 
they both measure the amorphous phase. The onset of melting by DSC does not 
correlate with the apparent onset of electric conductivity change, because the Tm 
measures the true solid-liquid transition while the TO is confounded by the pre-
melt Dielectric visco-elastic property of the blended drug.  
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Table V: A comparison of the DSC and DEA properties of PEG, Aspirin and ASA/PEG 
blend 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DRUG 
DSC DEA 
TM (
o
C) TP(
o
C) TO (
o
C) TA (
o
C) 
 
 
Polyethylene 
Glycol (PEG) 
 
 
Aspirin Pure (ASA) 
 
 
Blend ASA/PEG 
(10/90)w% 
 
 
 
59 
 
 
 
138 
 
 
54 
 
 
 
 
63 
 
 
 
144 
 
 
61 
 
 
 
46 
 
 
 
102 
 
 
56 
 
 
71 
 
 
 
151 
 
 
71 
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4.3   Characterization of Polymorphs 
 
4.3.1 DSC and DEA of Nifedipine Polymorphs 
 
The thermal and complimentary electrical behavior of nifedipine yields a 
better understanding of the various phase transitions between its polymorphs. 
Polymorph identification and associated electrical changes during melting and 
crystallization were recorded and discussed. The variations in physical 
properties were compared and related to the melting and crystallization 
mechanism. An attempt to prepare amorphous samples of nifedipine created 
“pseudo amorphous polymorphs”. These samplings contained crystalline and 
amorphous material as detected by PXRD and DSC/DEA.  
In this study the following are described: the metastable form B (Pseudo 
Amorphous form), with a melting range of 160-163oC, the thermodynamically 
stable form A (Pure), melting at 166-171oC, an enantiotropic third adaptation, 
form C (solvate), associated with the solvate desolvating and then melting at 133-
145 and 154-164oC, respectively. Endothermic desolvation of form C converted to 
form B with its unique melting temperature. The heat cool cycling DSC technique 
has given us quality repeatability data and an insight into the crystallization 
process. In the quest to reduce the particle size of the solvate, Form C, the 
pulverized sample converted to Form B. The heat cool cycle tests of nifedipine 
verified the stability of form A (pure) and the variation in form B (Pseudo 
Amorphous form).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
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Nifedipine Pure, Form A 
The DSC heat cool cycle evaluation for Nifedipine polymorphic form A 
(Pure) is summarized in table VI-1 and figure 32. The average melting properties 
of this phase were 166-171oC and a ΔHf of 116±2 J/g. The crystallization process 
observed after each heating cycle on the average crystallization temperatures (Tc 
& Tcp) were 145-134oC and the ΔHc was 105±7 J/g. There are no obvious 
additional endotherms from 0 to 150oC.  
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Figure 32: Heat-Cool-Heat-Cool-Heat DSC of Nifedipine Pure (Form A) 
 
However the DEA of form A, pure nifedipine revealed a repeatable at low 
frequencies from 0.1 to 1.0 Hz a 1st order transition at 93oC. This transition is due 
to a solvent either adsorbed water or dioxane (b.p. 101oC) at 2ppm. This solvent 
concentration is the ratio of the conductivity at a peak frequency, at 93oC and the 
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conductivity of the nifedipine liquid at 176oC i.e, 3.31x10-2 pS/cm at low 
frequency and 1.8x104 pS/cm at the same frequency in the melt, see figure 33. 
The overall change in conductivity from pure crystalline solid to amorphous 
liquid was 1.3x10-3 to 1.8x104 pS/cm or a change of 7 orders of magnitude. The 
DSC defines the melting of this polymorph. The overlay of DSC and DEA (see 
figure 33 & 34) again revealed a linear relationship of conductivity to 
temperature, this conductivity vs. temperature behavior occurred between 163 
and 171oC. This premelt phenomenon is called the Dielectric Visco-elastic 
Transition property (as explained above in the blends section).  
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Figure 33: DEA of Nifedipine Pure (Form A) 
 
The Tan delta (tanδ) DEA study confirmed molecular mobility within the 
sample peaking at 96 to 98oC for surface frequencies < 1 Hz. This transition 
probably due to a solvent, see figure 35. The second Tanδ transition at 166 to 
167oC is related to the solid liquid phase change. Tanδ from the repeat DEA run 
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(see figure 36) has 5 peaks at 36, 63, 85, 114 and 159oC. The 1st four peaks are 
probably due to desorption of water or dioxane and the 159oC is related to 
residual melting of nifedipine. 
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Figure 34: Overlay of DSC & DEA of Nifedipine Pure (Form A) 
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Figure 35: DEA 1
st
 run of Nifedipine Pure (Form A), Tanδ vs.Temperature 
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Figure 36: DEA 2
nd
 run of Nifedipine Pure (Form A), Tanδ vs.Temperature 
 
Nifedipine Form B (Pseudo Amorphous) 
 
This polymorph is semi-crystalline. The average melting temperature for 
this form is 163-169oC with a ΔHf of 103±1 J/g. The average crystallization 
occurred upon cooling from the melt between 140-133oC with an average ΔHc of 
79±8 J/g, see Table VI-2 and figure 37. To reduce the particle size of this 
polymorph it was pulverized resulting in melting at 162-168oC and a ΔHf of 
118±3 J/g. The average crystallization temperatures were 132-127oC and a wide 
variation in the ΔHc from 106 to 45 J/g, see table VI-3 and Figure 38.This 
observation is consistent with Kellen‟s study52 that Form B is less stable than 
Form A. Another Form B was prepared by cryogenic grinding of the original 
pseudo amorphous sample. It appears that the cryogenic grinding also converted 
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from form B to form A. Evidence for this change is based on the average melting 
temperatures, Tm = 162-169oC, compared with form A at 166-171oC and heat of 
fusions 113±2 J/g vs. form A at 116±2  J/g, see table VI-4 and figure 39.  
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Figure 37: Heat-Cool-Heat-Cool-Heat DSC of Nifedipine Pseudo Amorphous 1 
 (Form B) 
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Figure 38: Heat-Cool-Heat-Cool-Heat DSC of Nifedipine Pseudo Amorphous 1 
Pulverized (Form B) 
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Figure 39: Heat-Cool-Heat-Cool-Heat DSC of Nifedipine Pseudo Amorphous 2 
 (Form B) 
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Figure 40: DEA of Nifedipine Pseudo Amorphous 1 (Form B) 
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Figure 41: DEA of Nifedipine Pseudo Amorphous 1 Pulverized (Form B) 
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The DEA of Form B has 2 first order conductivity-temperature transitions 
at 60 and 102oC at 0.1 Hz (surface analysis frequency range from 0.1 to 10 Hz) 
which is interpreted as several forms of water desorption, see figure 40. The 
pulverized sample of form B only had the conductivity peak at 102oC and not at 
60oC. Grinding has removed the loosely bound adsorbed water at 60oC, see 
figure 41. 
 
Nifedipine Form B (Cryogenic grinding): 
 
The cryogenically cooled and pulverized sample is amorphous but 
contains a crystalline phase and is therefore semi-crystalline. The latter is 
observed in the PXRD studies where the amorphous band is accompanied by 
definitive interplanar spacings.  The DEA of this polymorph is represented in 
Figure 42-45. The crystalline phase in this sample is detected by DEA at 50oC 
with an electrical conductivity (k) of 0.292 pS/cm. The ultimate DEA amorphous 
phase after melting (determined by DSC) has a k value of 7.38 x 105 at 191oC that 
is 20oC above the DSC Tmp. This implies that the difference from the crystalline 
solid phase to the amorphous liquid phase changes by 106 pS/cm.  
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Figure 42: DEA 1
st
 run of Nifedipine Pseudo Amorphous 2 (Form B) 
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Figure 43: DEA 2
nd
 run of Nifedipine Pseudo Amorphous 2 (Form B) 
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Figure 44: DEA 3
rd
 run of Nifedipine Pseudo Amorphous 2 (Form B) 
 
There is however another transition that occurs prior to the melting (as 
detected by DSC). This is where the conductivity increases in a linear manner 
and is denoted as the pre-melt transition. The logarithm of the conductivity vs. 
the reciprocal temperature in Kelvin in the pre-melt transition range varies 
linearly with a correlation coefficient (R2) of >0.99. This unique conductivity 
behavior has been observed for the 20 L-amino acids in our lab.  
The Pseudo Amorphous 2 Nifedipine overlay of repeated DEA HCHCH 
runs shows the following variations recording only the heat cycle: Figure 45 and 
Table VII for details. The 2nd and 3rd heat run were identical and clearly 
differentiated from the crystalline phase change. At 50oC the crystalline phase 
has a k of 0.292 pS/cm while at the same temperature the 2nd run with a higher 
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amorphous content had a k of 2.73 pS/cm, i.e. a 10 fold increase. At 140oC the 
crystalline phase has a k of 1.66 x 102 and increases during the 2nd run to 3.55 x 
104 pS/cm or a 200 fold increase at this temperature. At 166 or 168oC the sample 
melted to form an amorphous phase and the 1st run k was 1.39x105 pS/cm and 
the 2nd run k was 3.94x105 pS/cm or a 2 fold increase for the small change in the 
temperature.  
          Table VII: Summary of Conductivity variations for multiple heating runs of  
                        Amorphous 2 Nifedipine 
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Figure 45: DEA Overlay of multiple runs of Nifedipine Pseudo Amorphous 2  
(Form B) 
 
Sample Run  Temperature Conductivity 
 number 
o
C PS/cm 
Amorphous 2 & 3 191 7.38 x 10
5
 
Amorphous 2 & 3 168 3.94 x 10
5
 
Amorphous 2 & 3 140 3.55 x 10
4
 
Amorphous 2 & 3 50 2.73 x 10
0
 
Crystalline 1 166 1.39 x 10
5
 
Crystalline 1 140 1.66 x 10
2
 
Crystalline 1 75 2.6  x 10
0 
 
Crystalline 1 50 2.92 x 10
-1        
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Calculation of crystalline and amorphous content 
 
The amorphous and crystalline content were determined at a 120oC, 
which is 52oC below the DSC melting of nifedipine. The difference between the 
amorphous DEA conductivity curve and the crystalline curve is recorded (see 
Figure 45). This variation is proportional to the total content of polymorph, i.e., 
amorphous and crystalline fractions of the polymorph. Next, we measure the 
crystalline portion of the variation and divide it by the total times 100 to yield a 
% crystalline, see Figure 45. The % amorphous content is the remainder from the 
last calculation.  The results of our evaluation are given in Table VIII for this 
polymorph of nifedipine.  
 
          Table VIII: Summary of calculations to determine % crystalline and amorphous  
  content in Nifedipine 2 Amorphous  
 
Run 
 
%Crystalline  %Amorphous 
1 77 23 
2 & 3 20 80 
 
 
Nifedipine Form C (Polymorph Solvate): 
 
The 1,4-Dioxane solvate of nifedipine is known. The heat cool cycle test 
and DEA method were used to determine collaborative and new properties of 
the solvate. The DSC curve of the solvate, (Figure 46) shows 3 endotherms; a 
solid-solid transition, 89-108oC with a heat of transition 6.7 J/g; next is the 
desolvation, 143-152oC with a heat of desolvation of 37 J/g; and a melting of 
nifedipine, 164-170oC with a ΔHf of 51 J/g. The melting properties after 
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desolvation indicate that Form B (Tm=163-169oC & ΔHf = 103 J/g) is derived from 
Form C. The difference in the ΔHf is probably related to the amount of 
crystallinity (50% = 51 J/g / 103 J/g*100). The heat cool testing cycle of form C, 
first heat desolvation 133-145oC and ΔH = 102 J/g for desolvation and melting. 
The 2nd and 3rd cycle melting temperature was 154-164oC with a decreasing heat 
of transition from 61 to 47 J/g. There was no apparent crystallization in the two 
cooling cycles, see table VI-5 and figure 47.  Grinding the solvate to increase 
surface area and solubility was next attempted. Pulverized solvate form C was 
not stable and produced form B. This interpretation is based on the pulverized 
solvate with a melting temperature of 160-168oC and the ΔHf of 99±4 J/g, and 
confirmed by its crystallization properties, see table 4.3.1-6 and figure 48.  
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Figure 46: DSC of Nifedipine Solvate (Form C) 
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Figure 47: Heat-Cool-Heat-Cool-Heat DSC of Nifedipine Solvate (Form C) 
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Figure 48: Heat-Cool-Heat-Cool-Heat DSC of Nifedipine Solvate Pulverized  
(Form C) 
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The DEA of nifedipine solvate form C is seen in figure 49. The DEA curve 
of Form C has one first order conductivity-temperature transition at 84oC at 0.1 
Hz (surface analysis frequency range from 0.1 to 10 Hz) which is interpreted as 
desorption of solvent 1,4-Dioxane. It is my interpretation that this transition is 
due to the absorbed solvent 1,4-dioxane at 5000ppm. This concentration is 
proportional to the ratio of the conductivity at a peak frequency at 84oC and the 
conductivity of the nifedipine liquid at 161oC i.e, 4.1x101 pS/cm at low frequency 
and 7.97x103 pS/cm at the same frequency in the melt, see figure 49. The DEA-
DSC overlay of the nifedipine solvate form C indicates that the desolvation 
process is causing a striking variation in the conductivity (pS/cm) vs. 
temperature, see figure 50.  
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Figure 49: DEA of Nifedipine Solvate (Form C) 
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Figure 50: DSC & DEA Overlay of Nifedipine Solvate (Form C) 
 
 
The pulverized sample of form C has two weak conductivity peaks at 65 
and 99oC.  Grinding has not reduced the amount of adsorbed water or solvent at 
65 and 99oC, see figure 51. The conductivity temperature profile from 130 to 
170oC is indicative of Nifedipine form B in this sample which is the result of the 
stress grinding of form C. This process is also observed in the DSC analysis. The 
DSC desolvation process (144-151oC) was not observed in the 2nd runs by DSC 
(158-166oC). The DEA conductivity does not increase rapidly after grinding from 
140 to 160oC (observed 1 to 10 pS/cm), while during desolvation the conductivity 
changed from 23 to 8000 pS/cm, see figures 49, 51 and 52.  
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Figure 51: DEA of Nifedipine Solvate Pulverized (Form C) 
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Figure 52: DSC overlay of Solvate & Desolvated Nifedipine 
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4.3.2 DSC and DEA of Tolbutamide Polymorphs 
 
The thermal and complimentary electrical behavior of tolbutamide yields 
a better understanding of the various phase transitions between its polymorphs. 
Polymorph identification and associated electrical changes during melting and 
crystallization were recorded and are discussed. The variations in physical 
properties were compared and related to the melting and crystallization 
mechanism. 
In this study the following are described: tolbutamide pure form , with a 
melting range of 125-128oC, form A, melting at 124-128oC, and form B melting at 
114-122oC. Form B is converted to form A with time or applied stress. The heat 
cool cycling DSC technique has produced a quality, repeatable data set and an 
insight into the crystallization process. The heat cool cycle tests of tolbutamide 
verified the stability of form A and the pure form.  
Tolbutamide Pure 
The heat cylces reduces the amount of crystalline content by 15%on the 
third heat, see table IX-1. The ΔHf for pure, varied from 120 J/g to 109 J/g to 102 
J/g through the cycles. The average ΔHf for this study is 110±9 J/g. The 
recrystallization of this polymorph during the cooling cycles yielded 
%crystallinity of 48% (of the original heat of fusion of 120 J/g) and 52% 
amorphous content. The second cooling cycle yielded %crystallinity of 38% (of 
the original heat of fusion of 120 J/g) and 62% amorphous content. The large 
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value for %relative error is indicative of factors affecting the crystallization 
process, see table IX-1and figure 53. 
 Table IX:          
 DSC heat cool cycle testing for Tolbutamide polymorphs    
           
  
Polymorphic 
Forms Tm Tmp ΔHf 
% 
ΔHf Tc Tcp ΔHc % ΔHc ΔT 
    oC oC J/g   oC oC J/g   oC 
                      
1 Tolbutamide Pure 127 129 120 100 73 62 58 48 67 
    124 128 109 91 70 56 46 38 72 
    123 127 102 85           
  Average 125 128 110 92 72 59 52 43 70 
  
Standard 
Deviation 2.08 1.00 9.07 7.55 2.12 4.24 8.49 7.07 3.54 
  %Relative Error 1.67 0.78 8.22 8.21 2.97 7.19 16.32 16.44 5.09 
                      
2 
Tolbutamide Form 
A  126 129 106 100 76 64 57 54 65 
    124 128 97 91 72 58 43 41 70 
    122 127 90 85           
  Average 124 128 98 92 74 61 50 48 68 
  
Standard 
Deviation 2.00 1.00 8.02 7.55 2.83 4.24 9.90 9.19 3.54 
  %Relative Error 1.61 0.78 8.21 8.21 3.82 6.96 19.80 19.35 5.24 
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Figure 53: Heat-Cool-Heat-Cool-Heat DSC of Tolbutamide Pure 
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Figure 54: Overlay of DEA multiple runs of Tolbutamide Pure 
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Evaluation of the tolbutamide polymorph by multiple runs of DEA is 
summarized in table X at 100Hz. The melted amorphous tolbutamide polymorph 
had an average conductivity of 3.7±0.4X106 pS/cm, see figures 54 & 55.  The two 
1st run crystalline samples had conductivities of < 1 at 40oc and < 3 pS/cm at 80 
oC, see figure 56. The 2nd run proved to be semi-crystalline, 16% crystalline and 
84% amorphous. 80oC was selected as the temperature to determine the % 
amorphous-crystalline content of the tolbutamide sample. The 1st sample, 1st run 
with the lower conductivity at 40 and 80oC as the 100% crystalline sample. The 
2nd sample 1st run had a slightly higher conductivity and we assumed it to be 
mostly crystalline. The 2nd sample 2nd run at 80oC had a significantly higher 
conductivity at 104 pS/cm. The amorphous and crystalline content were 
determined at 80oC which is 49oC below the DSC peak melting of tolbutamide. 
The difference between the amorphous DEA conductivity curve and the 
crystalline curve is recorded (see Figure 54). This variation is proportional to the 
total content of polymorph, i.e., amorphous and crystalline fractions of the 
polymorph. Next, we measure the crystalline portion of the variation and divide 
it by the total times 100 to yield a % crystalline, see Figure 54. The % amorphous 
content is the remainder from the last calculation.  The results of our evaluation 
are given in Table X for this polymorph of tolbutamide.  
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 Table X: Evaluation of Tolbutamide polymorph pure by DEA  
        
  CONDUCTIVITY (pS/cm) @            % CONTENT COMMENTS 
  ( Frequency=100Hz )    
SAMPLE RUN 40°C 80°C 140°C crystalline amorphous  
    (10-6)    
1 1 0.41 0.99 4.1 100 0 crystalline 
2 1 0.94 2.7 3.4 92 8 
semi-
crystalline 
2 2 136 3.9 X 104 3.7 16 84 
semi-
crystalline 
Average amorphous    3.7   3.7X10
6 PS/cm 
Standard Deviation    0.4    
%Relative Error    9.4    
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Figure 55: DEA 2
nd
 run of Tolbutamide Pure 
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Figure 56: DEA 1
st
 run of Tolbutamide Pure 
 
Tolbutamide A: 
The DSC heat cycles reduces the amount of crystalline content by 15% on 
the third heat, see table IX-2. The ΔHf for form A, varied from 106 J/g to 97 J/g to 
90 J/g through the cycles. The average ΔHf for this study is 98±8 J/g. The 
recrystallization of this polymorph during the cooling cycles yielded 
%crystallinity of 54% (of the original heat of fusion of 106 J/g) and 46% 
amorphous content. The second cooling cycle yielded %crystallinity of 41% (of 
the original heat of fusion of 106 J/g) and 59% amorphous content. The large 
value for %relative error is indicative of factors affecting the crystallization 
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process, see table IX-2 and figure 57. The relative DSC temperatures and heat 
changes for the tolbutamide polymorphs pure and form A were very similar.  
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Figure 57: Heat-Cool-Heat-Cool-Heat DSC of Tolbutamide A 
 
The 1st DEA run at 50oC had a conductivity of 0.87 pS/cm at 100 Hz. The 
2nd DEA run of the same polymorph at 50oC had a conductivity of 100 pS/cm at 
100 Hz. The 2nd run is obviously semi-crystalline at the start. The melted 
amorphous material from both runs had an average electrical conductivity 
1.8x106 pS/cm. At the DSC peak melt temperature at 130-132oC, the conductivity 
for the 1st run was 4.9x105 pS/cm and 2nd run was 9.8x105 pS/cm. 
The amorphous and crystalline content were determined at a 85oC, which 
is 43oC below the DSC peak melting of tolbutamide A. The difference between 
the amorphous DEA conductivity curve and the crystalline curve is recorded (see 
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Figure 58). This variation is proportional to the total content of polymorph, i.e., 
amorphous and crystalline fractions of the polymorph. Next, we measure the 
crystalline portion of the variation and divide it by the total times 100 to yield a 
% crystalline, see Figure 58. The % amorphous content is the remainder from the 
last calculation.  The results of our evaluation are given in Table XI for this 
polymorph of tolbutamide form A. The %crystalline in the 1st run was 100 and 
12% in the 2nd run. The % crystalline content in the 2nd run for tolbutamide pure 
and form A were similar, 16% and 12% respectively. 
Table XI: Evaluation of Tolbutamide polymorph A by DEA  
         
  CONDUCTIVITY (pS/cm) @            % CONTENT COMMENTS 
  ( Frequency=100Hz )     
SAMPLE RUN 50°C 85°C 130°C 143°C crystalline amorphous  
    (10-5) (10-6)    
1 1 0.87 8.0 4.9 1.7 100 0 crystalline 
1 2 100 2.4X104 9.8 1.8 12 88 
semi-
crystalline 
Average amorphous  7.4 1.8   1.8X10
6 PS/cm 
Standard Deviation  3.5 0.1    
%Relative Error   47 4.0    
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Figure 58: Overlay of DEA multiple runs of Tolbutamide A 
 
The low frequency analysis (0.1 to 1.0 Hz) of the solid phase changes in 
tolbutamide form A are viewed in figures 59 to 61. The amorphous phase has an 
average conductivity of 1.3X105 pS/cm. The %relative error is low at 140oC. The 
crystalline phase is detected at 56 to 82oC with a conductivity <3 pS/cm. The 2nd 
run of this sample containing a high amorphous content was accompanied with 
a significantly larger conductivity of 104 to 105. It is obvious to decern that the 2nd 
run is semi-crystalline even at 56oC where the conductivity is 181 vs. 0.16 for the 
initial sample which is crystalline. The crystalline amorphous content was 
measured at 80, 90 & 100oC with an average value of 16% crystalline content. 
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These determinations were similar to those used previously, see table XII & 
figure 61. 
Table XII: Evaluation of Tolbutamide polymorph A by DEA   
         
  CONDUCTIVITY (pS/cm) @             % CONTENT COMMENTS 
  ( Frequency=1.0Hz )     
SAMPLE RUN 56°C 82°C 128°C 140°C crystalline amorphous  
     (10-5)    
1 1 0.16 3.1 51 1.2 100 0 Crystalline 
1 2 181 1.1X104 1.1X105 1.3 16 84 
semi-
crystalline 
Average amorphous   1.3   1.3X10
5 PS/cm 
Standard 
Deviation    0.1    
%Relative Error    5.7    
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Figure 59: DEA 1
st
 run of Tolbutamide A 
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Figure 60: DEA 2
nd
 run of Tolbutamide A 
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Figure 61: Overlay of DEA 1
st
 & 2
nd
 run of Tolbutamide A 
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Tolbutamide B 
DSC heat cycle tolbutamide B is significantly different from both 
tolbutamide pure and Form A. Tolbutamide did not crystallize in either of the 
two cooling cycles. However, it did crystallize in the following heating cycle 
repeatably. This polymorph melting was 115 – 123oC with a ΔHf of 77 J/gm. 
Accompanying the melting of this polymorph was a solid-solid transition at 37 to 
39oC with a ΔHf of 6.7 J/gm. Separately a heat only evaluation of this polymorph 
had a solid-solid transition at 38-39oC and a heat of transition at 7.7 J/gm plus 
the melting at 114-122oC and a ΔHf of 70 J/g. The repeatability of this test can be 
evaluated by comparing the 1st heat cycle and the later heat curve that the 
transition and melting temperatures are reproducible and the ΔHf is in 
agreement with in 10%, see figures 62 and 63. There was no thermal event noted 
in the cooling cycles 2nd and 4th runs. However, there were obvious repeatable 
transitions in the 3rd and 5th runs with an exotherm (Exo1) 53-56oC and a ΔHc of 
54 J/g. Following the crystallization there was an additional melting (Endo 2) at 
80-98oC with a ΔHf of 14 J/g.  Prior to the melting (Endo 3) there was an 
additional exo peak between 100 and 103oC and a ΔHc of 13 J/g. Finally the ΔHf 
of this polymorph at 115 to 122oC was observed on the average 47 J/g (3rd and 5th 
Run), see table XIII Previous work in this lab by Kellen Dutra, observed 
tolbutamide B melting at 123-126oC with a ΔHf of 80 J/g, these melting 
properties were in good agreement with the values reported in this study. The 
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endothermic melting in run five 82 J/g was equal to exo crystallization heat of 85 
J/g. 
 
 
 
 
Table XIII:          
DSC heat cool cycle testing for Tolbutamide polymorph B   
    
Heating 
cycle       
Cooling 
cycle       
Cycle Run Tm Tmp ΔHf % ΔHf Endo/Exo Tc Tcp ΔHc Comment 
  oC oC J/g   oC oC J/g   
                    
1st Run 37 39 6.7 8.7 Endo 1       Solid-Solid  
  115 123 77 100 Endo 3       Melting 
2nd Run            No No No   
3rd Run 54 66 55 71 Exo 1       Crystallization 
  82 98 15 19 Endo 2       Transition 
  100 103 14 18 Exo 2       Crystallization 
  115 122 43 56 Endo 3       Melting 
4th Run           No No No   
5th Run 53 64 53 69 Exo 1       Crystallization 
  78 95 13 17 Endo 2       Transition 
  100 103 12 16 Exo 2       Crystallization 
  115 122 50 65 Endo 3       Melting 
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Figure 62: Heat-Cool-Heat-Cool-Heat DSC of Tolbutamide B 
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Figure 63: DSC of Tolbutamide B Heat only 
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Figure 64: Overlay of DEa 1
st
 &2
nd
 run of Tolbutamide B 
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Figure 65: DEA 1
st
 run of Tolbutamide B 
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Figure 66: DEA of 2
nd
 run of Tolbutamide B 
 
DEA of tolbutamide B comparing the 1st run crystalline form and the 2nd 
run semi-crystalline form can be seen in Figures 64 to 66. The ratio of the semi-
crystalline to crystalline conductivity 2nd run to 1st run, was 610 at 40oC, 1900 at 
85oC and 1300 at 100oC. This evaluation clearly shows that the DEA conductivity 
differentiates crystalline (1st run) and semi-crystalline (2nd run) tolbutamide B in 
the solid state. The amorphous phase above 114 to 123oC had high conductivity 
values of 2.5X105 for the 1st run and 1.8X105 for the 2nd run.  Following the 
protocol developed above for calculating crystalline-amorphous content below 
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the melting at 85oC, the 2nd run contains 13% crystalline and 87% amorphous, see 
Table XIV.  
 
Table XIV: Evaluation of Tolbutamide polymorph B by DEA  
         
    
CONDUCTIVITY 
(pS/cm)       
% 
CONTENT   COMMENTS 
    ( Freq=1.0Hz )             
SAMPLE RUN 40°C 85°C 100°C 132°C crystalline amorphous  
     10
-5
    
1 1 0.33 15 52 2.5 100 0 crystalline 
1 2 202 2.8X10
4
 6.5X10
4
 1.8 13 87 
semi-
crystalline 
Avg 
amor     2.2   
2.2X10
5
 
PS/cm 
 
A summary of the crystalline-amorphous content of the 2nd DEA runs of 
tolbutamide polymorphs: Pure, Form A and Form B is given in Table XV. The 
crystalline content of these three polymorphs on the average was 14 ± 2%. The 
amorphous content of these polymorphs was on the average 86 ± 2%. Varying 
the frequency from 1 to 100 Hz, did not cause a variation in the percent content. 
Table XV: Percent Crystalline-Amorphous Content in the solid 
state of Tolbutamide Polymorphs by DEA 
     
Table 
No Sample Frequency %crystalline %amorphous 
  Tolbutamide (Hz)     
          
5 Pure 100 16 84 
6 Form A 100 12 88 
7 Form A 1.0 16 84 
9 Form B 1.0 13 87 
          
  Average   14 86 
  SD   2.1 2.1 
  %RE   14 2.4 
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A summary of the Conductivity of the amorphous phase in tolbutamide 
polymorphs: Pure, Form A and Form B is given in Table XVI. The amorphous 
conductivity varied with the frequency. The 100 Hz conductivity was an order of 
magnitude larger than the 1.0 Hz conductivity, see results of form A at 1.0 and 
100 Hz in Table XVI. The conductivity is determined based on the loss factor and 
frequency. The 100 Hz frequency is used to measure bulk conductivity while the 
1 Hz frequency is measured at the surface of the interdigitated electrode. 
 
Table XVI: Conductivity of Amorphous Phase in Tolbutamide  
                 Polymorphs 
     
Table 
No Sample Frequency Amorphous Comment 
  Tolbutamide (Hz) Conductivity   
      10
-5
   
5 Pure 100 37 Bulk Analysis 
6 Form A 100 18 Bulk Analysis 
7 Form A 1.0 1.3 
Surface 
Analysis 
9 Form B 1.0 2.2 
Surface 
Analysis 
 
4.3.3 Solubility and Particle Size 
Nifedipine Solvate Form C and its pulverized form were the most soluble 
in the ethanol-water blends. The least soluble was Nifedipine Form B Pseudo 
Amorphous 1 Polymorph at 18% in 65 % ethanol and 35% water. However, 
enhanced solubility was observed for Form B Pseudo Amorphous 1 pulverized 
and its cryogenically pulverized form. The tolbutamide polymorphs pure, A and 
B were soluble to very soluble in 85% ethanol and 15% water, 97, 89 and 98% 
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respectively. Tolbutamide A was the least soluble in 65% ethanol and 35% water 
at 41% solubility, see figure 67 and tables XVII, XVIII, XIX. 
 
Percentage Solubility of Polymorphs 
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Figure 67: Solubility % of Polymorphs in Ethanol-water Blends 
 
 
 
Table XVII: Calculation of % Solubility of Polymorphs in Ethanol-Water Blends 
(65/35)w  
Solvent: 65% 
Ethanol       
Sample 
wt. of 
tube wt. of tube  
sample 
wt. wt. of tube 
residue 
wt. 
amt. 
dissolved % solubility 
  (gm) 
+ 
sample(gm) (gm) 
+ 
residue(gm) (gm) (gm)   
Tol pure 1.0104 1.0377 0.0273 1.0170 0.0066 0.0207 76 
Tol A  1.0008 1.0242 0.0234 1.0145 0.0137 0.0097 41 
Tol B 0.9933 1.0176 0.0243 0.9976 0.0043 0.0200 82 
Nif Pure 1.0245 1.0499 0.0254 1.0375 0.0130 0.0124 49 
Nif Amor 1 1.0068 1.0319 0.0251 1.0275 0.0207 0.0044 18 
Nif A1 Pul 0.9967 1.0217 0.0250 1.0101 0.0134 0.0116 46 
Nif Amor 2 1.0132 1.0389 0.0257 1.0313 0.0181 0.0076 30 
Nif Solvate 1.0042 1.0288 0.0246 1.0108 0.0066 0.0180 73 
Nif Sol pul 1.0070 1.0375 0.0305 1.0180 0.0110 0.0195 64 
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Table XVIII: Calculation of % Solubility of Polymorphs in Ethanol-Water Blends 
(75/25)w  
Solvent: 75% 
Ethanol       
Sample 
wt. of 
tube wt. of tube  
sample 
wt. wt. of tube 
residue 
wt. 
amt. 
dissolved 
% 
solubility 
  (gm) 
+ 
sample(gm) (gm) 
+ 
residue(gm) (gm) (gm)   
Tol pure 0.9953 1.0266 0.0313 0.9963 0.0010 0.0303 97 
Tol A  1.0124 1.0394 0.0270 1.0203 0.0079 0.0191 71 
Tol B 1.0050 1.0329 0.0279 1.0094 0.0044 0.0235 84 
Nif Pure 1.0037 1.0290 0.0253 1.0145 0.0108 0.0145 57 
Nif Amor 1 0.9952 1.0197 0.0245 1.0140 0.0188 0.0057 23 
Nif A1 Pul 0.9935 1.0224 0.0289 1.0053 0.0118 0.0171 59 
Nif Amor 2 1.0275 1.0559 0.0284 1.0406 0.0131 0.0153 54 
Nif Solvate 1.0047 1.0329 0.0282 1.0082 0.0035 0.0247 88 
Nif Sol pul 1.0124 1.0391 0.0267 1.0158 0.0034 0.0233 87 
 
 
Table XIX: Calculation of % Solubility of Polymorphs in Ethanol-Water Blends (85/15)w  
Solvent: 85% 
Ethanol       
Sample 
wt. of 
tube wt. of tube  
sample 
wt. wt. of tube 
residue 
wt. 
amt. 
dissolved 
% 
solubility 
  (gm) 
+ 
sample(gm) (gm) 
+ 
residue(gm) (gm) (gm)   
Tol pure 1.0291 1.0554 0.0263 1.0300 0.0009 0.0254 97 
Tol A  1.0063 1.0379 0.0316 1.0099 0.0036 0.0280 89 
Tol B 1.0180 1.0430 0.0250 1.0186 0.0006 0.0244 98 
Nif Pure 1.0011 1.0261 0.0250 1.0078 0.0067 0.0183 73 
Nif Amor 1 0.9898 1.0168 0.0270 1.0051 0.0153 0.0117 43 
Nif A1 Pul 1.0066 1.0372 0.0306 1.0166 0.0100 0.0206 67 
Nif Amor 2 1.0024 1.0307 0.0283 1.0077 0.0053 0.0230 81 
Nif Solvate 1.0068 1.0323 0.0255 1.0084 0.0016 0.0239 94 
Nif Sol pul 0.9974 1.0227 0.0253 0.9983 0.0009 0.0244 96 
 
 
Nifedipine Polymorphs 
The polymorphs of the nifedipine solubility study are pure, Form B 
Pseudo Amorphous 1, Pseudo Amorphous 1 pulverized, Pseudo Amorphous 2, 
Form C nifedipine solvate and its pulverized form. Nifedipine pure form 
solubility varied when exposed to 65, 75, 85% ethanol blends with water from 49, 
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57, 73% respectively. Nifedipine Amorphous 1 of form B, solubility varied when 
exposed to 65, 75, 85% ethanol blends with water from 18, 23, 43% respectively. 
Nifedipine amorphous 1 pulverized of form B, solubility varied when exposed to 
65, 75, 85% ethanol blends with water from 46, 59, 67% respectively. This 
pulverized form B % solubility is similar to nifedipine pure form. Particle size 
analysis of the latter polymorphs suggest that the pure form structure is 
contributing to its solubility while the smaller nifedipine amorphous 1 
pulverized is controlling its solubility,  
Percentage Solubility of Nifedipine Polymorphs 
in Ethanol-Water Blends
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Figure 68: Bar graph - Solubility % of Nifedipine Polymorphs 
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               10mm=250μ 
Figure 69: Photo microscopic picture of Nifedipine Pure crystals 
So both forms are similar in solubility. The particle size (area 
measurement at 40X) is 70:30:20 for pure: Form B: Form B pulverized, see figure 
68, 69, 70, 71. The cryogenic grinding of form B produced on average a smaller 
particle size than amorphous 1 form B. The particle size ratio for the 2 pulverized 
samples was (pulverized form B/cryogenic pulverized form B) 20 to 10, compare 
figures 71, 72 & 73. The cryogenic sample solubility increased at 85% ethanol and 
was same at 75% ethanol and decreased at 65% ethanol.  
 
              10mm=250μ 
Figure 70: Photo microscopic picture of Nifedipine Amorphous 1 crystals 
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             10mm=250μ 
Figure 71: Photo microscopic picture of Nifedipine Amorphous 1 Pulverized crystals 
 
            10mm=250μ 
Figure 72: Photo microscopic picture of cryogenically pulverized Nifedipine Amorphous 
crystals 
The %solubility of these polymorphs vs. %ethanol in the water blends is 
viewed in figure 74; the amorphous 1 form B curve fit was clearly different than 
the curve fit for the 2 pulverized samples. The pulverizing process clearly 
increased the solubility in ethanol water blends at all concentrations, see tables 
XX & XXI. The nifedipine solvate polymorph was more soluble than pure form 
for all concentrations of ethanol-water blends. The presence of the solvate greatly 
enhanced the solubility of nifedipine pure, see figures 68 & 74. 
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Percentage Solubility of Pseudo Amorphous Nifedipine 
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Figure 73: Solubility % of Pseudo Amorphous Nifedipine (Form B) 
 
 
Table XX : Percentage Solubility Polymorphs in  
Ethanol-Water Blends   
Sample 
65% 
ethanol 
75% 
ethanol 
85% 
ethanol 
Tol pure 76 97 97 
Tol A  41 71 89 
Tol B 82 84 98 
Nif Pure 49 57 73 
Nif Amor 1 18 23 43 
Nif A1 Pul 46 59 67 
Nif Amor 2 30 54 81 
Nif Solvate 73 88 94 
Nif Sol pul 64 87 96 
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Table XXI: Percentage Solubility of 
Tolbutamide  
 Polymorphs in Ethanol-Water Blends 
Sample 
65% 
ethanol 
75% 
ethanol 
85% 
ethanol 
Tol 
pure 76 97 97 
Tol A  41 71 89 
Tol B 82 84 98 
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Figure 74: Solubility % of Nifedipine pure and solvate forms 
Tolbutamide Polymorphs 
The three polymorphic forms evaluated for their % solubility were pure, 
form A and form B. The average solubility of the tolbutamide polymorphs pure 
and B are greater then form A at all concentrations of the ethanol-water blends, 
see figures 75, 76 & table XXII.  
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Table XXII : Percentage Solubility of Nifedipine  
Polymorphs in Ethanol-Water Blends 
Sample 
65% 
ethanol 
75% 
ethanol 
85% 
ethanol 
Nif Pure 49 57 73 
Nif Amor 1 18 23 43 
Nif A1 Pul 46 59 67 
Nif Amor 2 30 54 81 
Nif Solvate 73 88 94 
Nif Sol pul 64 87 96 
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Figure 75: Bar graph – Solubility % of Tolbutamide polymorphs 
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Percentage Solubility of Tolbutamide Polymorphs 
in Ethanol-Water Blends
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Figure 76: Solubility % of Tolbutamide polymorphs 
Particle size analysis of these polymorphs indicated a wide range of sizes 
of aggregates and log-like particles with approximate areas of 1.0 to 8.0 mm2 . 
Therefore particle size of these three polymorphs of tolbutamide does not appear 
to be a contributing factor in the solubility determination, see figures 77, 78 & 79. 
 
            10mm=2500μ 
Figure 77: Photo microscopic picture of Tolbutamide Pure crystals 
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               10mm=250μ 
Figure 78: Photo microscopic picture of Tolbutamide Form A crystals 
 
 
              10mm=250μ 
Figure 79: Photo microscopic picture of Tolbutamide Form B crystals 
 
 
 
4.3.4 Scanning Electron Microscope (SEM) 
 
Tolbutamide Polymorphs 
The tolbutamide polymorphs morphology distinguished the three forms 
at 350X magnification, See Figure 80. Tolbutamide pure appears as aggregates. 
Form A morphology is rectangular prisms and Form B is a combination of plates 
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and prisms. The morphology at 40X magnification reported in solubility section 
showed large log like structures representing the gross structure while the fine 
structure is seen at 350X by SEM. 
 
 
 
 
Figure 80: SEM of form “pure”, form A and form B of Tolbutamide 
 
Nifedipine Polymorphs 
 
The Nifedipine polymorphs morphology are distinguished the two forms pure and 
cryogenically pulverized amorphous, form B, at 1000X and 350X magnification 
respectively, See Figure 81. Nifedipine pure appears as plates and prisms. Form B 
morphology are aggregates which are probably the plates, but this polymorph was 
cryogenically pulverized. The latter is more soluble with a 85% ethanol- 15% water 
blend. 
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Figure 81: SEM morphology of a pure crystalline and an amorphous form B of 
Nifedipine 
 
 
4.3.5 Ultraviolet-Visible Spectroscopy 
 
Nifedipine Polymorphs 
Nifedipine had a diverse UV spectrum due to the various functionalities 
in the molecular structure. The UV absorption spectrum of nifedipine 
polymorphs exhibit a long wavelength band and maximum in the range 320-360 
nm that tails beyond 400 nm as well as more intense bands at 235 and 280 nm43. 
In this study, the maximum wavelengths varied slightly but were arranged into 
groups within ±20 nm, for example, 235±20 nm probably due to ortho nitro 
group associated with the benzene ring; 280±15 nm probably also related to nitro 
aromatic; 340±20 nm probably related to the dihydropyridine structure; 400±20 
nm probably related to the meta-diesters and dihydropyridine, see table XXIII. 
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Table XXIII: Wavelngths (nm) UV analysis of Nifedipine polymorphs 
NIF PURE NIF A1 NIF A1P NIF A2 NIF SOL NIF SOL P 
215 215 210 205 205 205 
225 225 230 225 225 225 
 245 245 245 245  
  255  255  
 275 270   260 
   280 280 280 
290    295 290 
310  300  340  
320 325 360 355   
330    420  
345      
370 370 370    
400   405  405 
 
 
Tolbutamide Polymorphs 
The tolbutamide UV absorption spectrum showed 3 major wavelength 
maxima at 256, 262 and 274 nm. The key wavelength selected for a tolbutamide 
assay was 274-276 nm, not the peaks at shorter wavelengths44. In this study, the 
maximum wavelengths varied and are arranged into groups, for example, 225-
230 nm probably due to the double bond conjugation with the sulfur oxygen, 
250-255 nm probably due to para-substituted aromatic ring; 260 nm probably 
also related to the sulfur dioxide aromatic ring; 270-275 nm probably associated 
with the aromatic sulfonamide conjugation, see table XXIV. 
Table XXIV: Wavelngths (nm) UV analysis of Tolbutamide 
polymorphs 
       TOL PURE            TOL A            TOL B 
65% 85% 65% 85% 65% 85% 
199  205 215 210 200 
210    220 215 
225 230 230 225 230 230 
 240     
255   250  250 
  260  260  
275 275 275 270  270 
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Figure 82: UV spectrum of Tolbutamide Polymorph 
 
 
4.3.6 Powder X-ray diffraction Analysis 
  A comparison of the PXRD curves of polymorphic forms of tolbutamide A 
and B are given in figure 83. There are 22 interplanar distances recorded from 5 
to 40 o2Θ. The intensities of both these polymorphs were essentially the same 
except at 13.0, 26.4, 35.4 o2Θ or dÅ 6.82, 3.40, 2.59 respectively. At these 3 
interplanar distances the intensities were significantly greater for B than A. this 
implies that those diffraction planes at their respective (hkl) Miller indices are 
more prevalent in B than in A. There is a preferred orientation along the 6.82 Å 
diffraction plane in Form B. 
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   Figure 83: PXRD of tolbutamide polymorphs 
 
The nifedipine polymorphs pure and solvate are distinctly different as seen in 
figure 84. Key differences for the pure form are at 8.0, 12.0, 16.3, 19.5 and 24.5 o2Θ 
and for the solvate at 13.0, 15.8, 20.0, 20.5, 23.8 and 24.5 o2Θ. The attempt to make 
an amorphous form was partially successful since the two amorphous forms 
contain a number of diffraction peaks. The semi-crystalline phase in the 
amorphous forms appears to be that of the pure form. 
 
Figure 84: PXRD of Nifedipine Pure and polymorphs 
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A thorough search of the literature for the structural aspects of the various 
polymorphic forms of tolbutamide and nifedipine were not detected. At this 
time, the crystal class, space group, unit cell length and angles for the polymorph 
studied need to be determined. 
 
4.3.7 Fourier Transform Infrared spectroscopy 
 
Tolbutamide Polymorphs 
From the measured FTIR spectrums of the polymorphs, it appears that the 
wave numbers and intensities (absorbance) are semi-quantitatively the same. The 
key functional groups monosubstituted amide, carbonyl, para disubstituted 
benzene, NH bend/C-N stretch, asymmetric stretch of sulfonamide, tertiary 
butyl, symmetric stretch of sulfonamide were compared directly for each 
polymorph. The wave number position and absorbance were with in reasonable 
degree of scientific certainty to be similar, see figures 85, 86 and 87. A detailed 
inspection of the absorbance for each wave number showed polymorph A is 
identical to polymorph B and pure is slightly less for certain wave numbers, 
tables XXV, XXVI. 
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Figure 85: FTIR spectrum of Tolbutamide Pure 
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Figure 86: FTIR spectrum of Tolbutamide A polymorph 
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Figure 87: FTIR spectrum of Tolbutamide B polymorph 
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Table XXV: Evaluation of Tolbutamide polymorphs by 
FTIR 
      
Wavenumber Pure Form A Form B*   
(cm-1)         
2924 1.30 1.80 1.6   
2855 0.98 1.40 1.4   
1377 0.49 0.84 0.8   
1158 0.80 0.82 0.74   
1660 0.90 0.78 0.72   
1554 0.62 0.69 0.64   
* Absorbance corrected for varying pathlength   
 
 
Table XXVI: Wavenumbers (cm-1) and suggested assignments derived from the  
 FTIR spectra of Tolbutamide Polymorphs 
Tol P Tol A Tol B Assignment 
3325 3325 3325 NH Stretch 
3092    
2924 2924 2924  
2855 2855 2854 Aromatic methyl 
 2724   
 1918 1918  
1702 1702 1702 Mono Substituted Amide 
1661 1660 1660  
1598 1598   
1554 1554 1553 NH Bend/C-N Stretch (Mono Substituted Amide) 
1462 1462 1461  
1377 1377 1377 Asymmetric stretch of Sulfonamide 
1336 1336 1336  
1311 1310   
1248 1247 1247 Tertiary Butyl 
1221 1220   
1159 1158 1158 symmetric stretch sulfonamide 
1121    
1094 1092 1092 Amide 
1002 1001 1001  
 936   
900 900 899  
816 815 815 Para Substituted Benzene 
726 724 724 -(CH2)3-(CH3)/CH Rock 
660 660   
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Nifedipine Polymorphs 
Nifedipine FTIR spectra, both the wave number and relative intensities 
(absorbance), are similar. Upon close scrutinity, FTIR curves vary slightly with 
wave numbers but with clear changes in relative intensity. These variations were 
also observed by Chan and Fleming28. The 1679 cm-1 band in nifedipine pure 
(C=O stretch) shifted to 1687 cm-1 in the solvate polymorph (see figure 92) with  
1, 4 dioxane, plus an additional peak at 1700 cm-1. The 1226 cm-1 band in 
nifedipine pure (-C-C-O ester) shifted to 1220 cm-1 in the solvate polymorph, a 
change of 6 cm-1, while the literature28 indicates a 12 cm-1 change, from 1227 cm-1 
to 1215 cm-1. The 793 cm-1 band in nifedipine pure shifted to 785 cm-1 in the 
solvate polymorph, a change of 8 cm-1, while the literature28 indicates a 9 cm-1 
change, from 793 cm-1 to 784 cm-1, see table XXVII. The pulverized solvate 
polymorph (see figure 93) partially converted to the pure form as evidence by the 
shift to 1679 cm-1 and the absence of 1700 cm-1 band. This observation was also 
detected in this study by DSC and DEA. Further interpretation of the solvate 
FTIR spectra re. pure polymorph spectra reveals that the heterocyclic ether, 
dioxane, appears to be associated with the changes in the ester functionalities of 
nifedipine. This suggests that the dioxane is in close proximity to the ester in the 
nifedipine solvate polymorph. The DSC and DEA of nifedipine pseudo 
amorphous forms (Form B), see figures 89-91, showed this form to be semi-
crystalline. The FTIR of this form has structural wave numbers related to the 
pure form (crystalline) see figure 88, with some wave number being identical and 
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others with a slight variation. The amorphous forms appear to have structural 
features similar to the pure form. Pulverizing or grinding, converted the 
polymorph Form B to Form A. The methodology developed in the study is 
invaluable in optimizing pharmaceutical formulations and aiding drug delivery.  
Table XXVII: Wavenumbers (cm-1) and suggested assignments derived from the FTIR spectra of  
 Nifedipine Polymorphs    
NIF P NIF A1 NIFA1 P NIFA2 NIF SOL NIF SOL P Assignment 
 3329 3328 3330    
3320      NH Stretch 
     3287  
     3229  
3100      C-H aromatic stretch  
 2938      
2923  2925 2923 2924 2921 C-H aliphatic stretch  
 2856 2855 2854 2854   
2722 2725 2725 2725  2725  
    1700   
1679 1672 1679 1679 1687 1679 carbonyl stretch 
1645  1646 1646 1650 1650 C=C stretch 
    1632 1631  
1622 1626  1624    
1573 1576 1574   1575 NH scissors o.o.p 
1528 1526 1529 1528 1526 1525 Asymmetric NO2 
1463 1462 1462 1463 1462 1462  
1377 1377 1377 1377 1377 1377  
1347 1348 1349 1349 1350 1351 symmetric NO2 
1311  1309 1309    
 1305   1306 1305  
1268       
1226 1221 1226 1226    
    1220 1218 -C-C-O ester 
1188 1186 1188 1188    
    1178 1177  
 1148      
1120 1118 1120 1120 1113 1112  
1052 1050 1052 1052 1052 1052 1,2 substituted aromatic ring 
1020 1020 1020 1021 1019 1018  
953 950   950 950 Dihydropyridine ring (?) 
857 858 858 858 861 861  
828 830  830 833 833 Ring CH  
793 791 793 793 785 785  
744 745 744 741 750 749  
712 712 712 712 709 709  
686   686    
    669 670  
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Figure 88: FTIR spectrum of Nifedipine Pure (Form A) 
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Figure 89: FTIR spectrum of Nifedipine Pseudo Amorphous 1(Form B) Polymorph 
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Figure 90: FTIR spectrum of Nifedipine Pseudo Amorphous 1pulverized (Form B) Polymorph 
  145 
16
79
.3
60
15
28
.6
51
14
62
.5
36
13
77
.4
97
13
49
.0
14
13
09
.1
08
12
26
.2
07 11
88
.7
31
11
19
.7
63 1
02
0.
93
6
10
52
.2
69
85
7.
69
3
82
9.
68
0
80
6.
89
7
79
3.
16
2
74
4.
30
4
71
2.
61
6
68
5.
81
3
2925.729, 1.08
28
54
.5
63
3330.308, 11.36
5001000150020002500300035004000
0
10
20
30
40
50
60
Nifidipine Amorphous 2
Wav enumbers
%
 
T
r
a
n
s
m
i
t
t
a
n
c
e
 
Figure 91: FTIR spectrum of Nifedipine Pseudo Amorphous 2(Form B) Polymorph 
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Figure 92: FTIR spectrum of Nifedipine Solvate (Form C) Polymorph 
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Figure 93: FTIR spectrum of Nifedipine Solvate Pulverized (Form C) Polymorph 
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CHAPTER V 
CONCLUSIONS AND FUTURE STUDIES 
5.1 Conclusions 
The following is a summary of the studies. The PEG melting peak 
temperature both in this study and in the literature increases with an increase in 
molecular weight following a polynomial curve fit. The percent crystallinity 
based on the ΔHf variation decreases with increase in molecular weight. Percent 
solubility in water decreased with molecular weight, which suggests that the 
optimum PEG, as an excepient is from 4000-8000. The degree of supercooling 
increases with molecular weight. The characterization of the PEG as a function of 
molecular weight has lead to a better understanding of the selection for a drug 
formulation, for example high concentration of PEG with a low dose of drugs. 
Co-crystallization of low dose drug blends has been confirmed by DSC 
and DEA. All three drugs (Aspirin, Naproxen, Mefenamic acid) studied appear 
not to crystallize and are therefore amorphous at room temperature. PEG is 
known to enhance crystallinity paired with an amorphous material in intimate  
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contact. DSC and DEA measure amorphous content of the drug, excepient and 
blends, is determined only after complete melting (TA is directly related to TP). 
These low drug dose blends are significantly more soluble in water. The 
enhanced solubility is due to the blend particle size being much smaller than the 
drug or PEG. With an increase in the blend heat of fusion the relative particle 
size decreases which effects solubility.  
Two crystal forms of Tolbutamide, form A and form B were prepared but 
form B was unstable and with time readily converted to form A. Two crystal 
forms of Nifedipine were prepared and identified as Form C (1,4-dioxane 
solvate) and form B (the pseudo  amorphous form). Form A (Nifedipine “pure”) 
is the commercially available product. 
The structures of the polymorphs were successfully characterized by 
Optical Microscopy, SEM, PXRD, FTIR and UV-Visible Spectroscopy. The 
properties of the polymorphs were confirmed by solubility tests, DSC and DEA. 
A unique thermal analytical method for evaluating polymorphic solids based on 
electrical conductivity analysis has been developed and established. 
Conductivity changes of 10-2 to 107 occur at solid phase changes, for example, the 
solid-liquid transition, melting. Conductivity changes of 101 to 103 occur at minor 
transitions associated with solvent desorption, deslovation, solid-solid 
transitions and crystallization. Electrical conductivity differentiates crystalline 
and amorphous drugs. In the solid state the conductivity was significantly 
greater for the amorphous drug than the crystalline solid drug. A new unique 
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analytical procedure has been developed to semi-quantitatively determine the 
percent amorphous and crystalline content in the solid state. This protocol is 
based on the significant conductivity difference between the crystalline solid and 
the amorphous liquid. Some drugs that recrystallize will have a crystalline 
content of 80-90% and amorphous content 10-20%. Other drugs, for example, 
lidocaine HCl, do not recrystallize and application of this protocol yield 5-10% 
crystalline content and 90-95% amorphous. 
 An important feature of the characterization studies focused on drug 
solubility. The solubility of 3 polymorphic forms of tolbutamide were 
determined, forms pure and B are more soluble than A. The PXRD structure of 
form B contains a specific orientation with inter-planar distances at 6.82 and 3.40 
Å; the obviously oriented structure is contributing to the lower melting point and 
enhanced solubility. The morphology of the polymorphs is clearly delineated by 
optical microscopy and SEM. FTIR spectra of tolbutamide polymorphs were 
essentially identical. 
 The solubility of nifedipine polymorphic forms was determined by a 
classical weight percentage method in ethanol-water blends. The solvate form 
was the most soluble, probably related to the solvate dioxane, a heterocyclic 
ether. Pulverizing or grinding of the pseudo-amorphous polymorphs rendered 
the samples with a decreased particle size and increased solubility. Polymorphic 
solvate crystals are vulnerable since grinding the sample, the solvate structure is 
lost. The pseudo-amorphous polymorphic forms contained a crystalline phase, 
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identified as the pure form by PXRD. The morphology of the nifedipine 
polymorphs is clearly differentiated by optical microscopy and SEM. The 
dioxane solvent appears to be associated with the pyridine structure NH and in 
close proximity to ester functionality as detected by FTIR spectroscopy. 
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5.2 Future Studies 
1. Determine the effect of relative humidity on the physical properties  of the 
nifedipine and tolbutamide polymorphic forms. 
2. Differentiating the polymorphic forms by raman spectroscopy and solid 
state NMR spectroscopy, further quantify the structure of polymorphs. 
3. Develop a phase diagram to establish stable and metastable forms of the 
polymorphs 
4. Develop high dose PEG and low dose of the polymorphic drugs 
5. Develop high dose water soluble excipients and low dose of polymorphic 
drugs 
6. Determine the molecular position of dioxane in the nifedipine solvate 
polymorph. 
7. Determine the effect of various wavelengths of light on the stability of the 
nifedipine polymorphs. 
8. Quantify the Amorphous-Crystalline content of drugs by DEA and DSC. 
9. Develop formulations with a wide range of PEG molecular weights. 
10. Develop a high dose PEG with a molecular weight of 4000 with Aspirin, 
Mefenamic acid and Naproxen. 
11. Determine other drugs which do not recrystallize after melting i.e., they 
are amorphous at ambient temperatures. Use these drugs in low dose 
blends with PEG and other water soluble excipients. 
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